**MEDICATION(S)**
ACTEMRA 200 MG/10 ML VIAL, ACTEMRA 400 MG/20 ML VIAL, ACTEMRA 80 MG/4 ML VIAL

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy. Systemic Juvenile Idiopathic arthritis (SJIA) (Initial): Diagnosis of active SJIA. Failure, contraindication, or intolerance to one NSAID or systemic glucocorticoid. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of active PJIA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
All uses (Initial): Prescribed by or in consultation with a rheumatologist.

**COVERAGE DURATION**
All uses (Initial, reauth): 12 months

**OTHER CRITERIA**
All uses (Reauth): Documentation of positive clinical response to Actemra therapy. All indications (Initial, reauth): Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Actemra in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].
ACTEMRA SC

**MEDICATION(S)**
ACTEMRA 162 MG/0.9 ML SYRINGE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy. Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Actemra in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
RA (Initial): Prescribed by or in consultation with a rheumatologist.

**COVERAGE DURATION**
RA (initial, reauth): 12 months

**OTHER CRITERIA**
RA (Reauth): Documentation of positive clinical response to Actemra therapy. Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Actemra in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].
ADAGEN

MEDICATION(S)
ADAGEN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
Excluded if patient has severe thrombocytopenia

REQUIRED MEDICAL INFORMATION
Adenosine deaminase (ADA) deficiency: Diagnosis of ADA deficiency in a patient with severe combined immunodeficiency disease (SCID) AND patient is not a suitable candidate for, or who has failed, bone marrow transplantation, hematopoietic stem cell transplant, or gene therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ADAPALENE

MEDICATION(S)
ADAPALENE 0.1% CREAM, ADAPALENE 0.1% GEL, ADAPALENE 0.3% GEL, ADAPALENE 0.3% GEL PUMP

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acne (initial): One of the following: A) Younger than 26 years of age OR B) Both of the following: 26 years of age or older AND Diagnosis of acne.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
ADCIRCA

MEDICATION(S)
ADCIRCA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy.
ADEMPAS

MEDICATION(S)
ADEMPAS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH AND PAH is symptomatic AND One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. Chronic thromboembolic pulmonary hypertension (CTEPH) (Initial): One of the following: A) Both of the following: 1) Diagnosis of inoperable or persistent/recurrent CTEPH and 2) CTEPH is symptomatic OR B) Patient is currently on any therapy for the diagnosis of CTEPH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH, CTEPH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH, CTEPH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA
PAH, CTEPH (Reauth): Documentation of positive clinical response to therapy.
AFINITOR

MEDICATION(S)
AFINITOR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Diagnosis of SEGA associated with TSC that requires therapeutic intervention but patient is not a candidate for curative surgical resection. Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma AND History of failure, contraindication, or intolerance to SUTENT (sunitinib) or NEXAVAR (sorafenib). Neuroendocrine tumors of pancreatic origin (pNET): Diagnosis of progressive pNET that are unresectable, locally advanced, or metastatic. Renal angiomyolipoma: Diagnosis of renal angiomyolipoma and TSC AND Patient does not require immediate surgery. Breast Cancer: Patient is a postmenopausal woman AND Diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer AND History of failure, contraindication, or intolerance to FEMARA (letrozole) or ARIMIDEX (anastrozole) AND Afinitor will be used in combination with AROMASIN ( exemestane). Neuroendocrine tumors of gastrointestinal (GI) or lung origin: Diagnosis of progressive, well-differentiated, non-functional NET of GI or lung origin AND patient has unresectable, locally advanced or metastatic disease.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
All Indications: 12 months

OTHER CRITERIA
All Indications: Approve for continuation of prior therapy.
AFINITOR DISPERZ

MEDICATION(S)
AFINITOR DISPERZ

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Subependymal Giant Cell Astrocytoma (SEGA): Diagnosis of SEGA associated with tuberous sclerosis complex (TSC) that requires therapeutic intervention but patient is not a candidate for curative surgical resection

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ALDURAZYME

MEDICATION(S)
ALDURAZYME

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Mucopolysaccharidosis I: confirmed diagnosis of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), OR confirmed diagnosis of Scheie form of Mucopolysaccharidosis I (MPS I) who have moderate to severe symptoms.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
ALECENSA

MEDICATION(S)
ALECENSA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): A) Diagnosis of metastatic NSCLC AND B) Patient has anaplastic lymphoma kinase (ALK)-positive disease as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND C) History of failure, contraindication, intolerance, or progressed on XALKORI (crizotinib)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of therapy.
ALOXI

MEDICATION(S)
ALOXI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chemotherapy-induced nausea and vomiting - Prophylaxis, Postoperative nausea and vomiting - Prophylaxis.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
May be covered under Part D if it does not meet the coverage criteria under Part B.
ALPHA-1 PROTEINASE INHIBITORS

MEDICATION(S)
ARALAST NP, GLASSIA, PROLASTIN C, ZEMAIRA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency: All of the following: A) Patient has an alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency AND B) Diagnosis of emphysema AND C) One of the following: 1) Patient has a high risk phenotype: PiZZ, PiZ(null), Pi(null)(null) OR 2) Patient has serum alpha-1 antitrypsin concentrations of less than 11 ?M/L (80 mg/dL) AND D) One of the following: FEV1 level is between 30% and 65% of predicted OR the patient has experienced a rapid decline in lung function (i.e., reduction of FEV1 more than 120 mL/year) that warrants treatment.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
ALUNBRIG

MEDICATION(S)
ALUNBRIG

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC. Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. Trial and failure or intolerance to Xalkori (crizotinib).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
AMPYRA

MEDICATION(S)
AMPYRA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS) (initial): Diagnosis of MS. Physician confirmation that patient has difficulty walking (eg, timed 25 foot walk test). One of the following: expanded disability status scale (EDSS) score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
MS (Initial): Prescribed by or in consultation with a neurologist.

COVERAGE DURATION
MS (Initial): 6 months. (Reauth): 12 months.

OTHER CRITERIA
MS (Reauth): Physician confirmation that the patient's walking improved with Ampyra therapy. One of the following: EDSS score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).
ANADROL-50

MEDICATION(S)
ANADROL-50

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Anemia (initial): Diagnosis of anemia caused by deficient red cell production AND History of failure or intolerance to standard therapies for anemia (ie, erythropoiesis-stimulating agents, immunosuppressants) AND Treatment will not replace other supportive measures (e.g., transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy, corticosteroids)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Initial and reauth: 12 months

OTHER CRITERIA
Anemia (reauth): patient has experienced an objective improvement in anemia (e.g., increased hemoglobin, increased reticulocyte count, reduction/elimination for need of blood transfusions)
MEDICATION(S)
APOKYN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
PD (Initial, reauth): Patient is using Apokyn with any 5-HT3 antagonist (eg, ondansetron, granisetron, dolasetron, palonosetron, alosetron)

REQUIRED MEDICAL INFORMATION
Parkinson's disease (PD) (Initial): Diagnosis of advanced PD. Patient is experiencing acute intermittent hypomobility (defined as off episodes characterized by muscle stiffness, slow movements, or difficulty starting movements). Patient is receiving Apokyn in combination with other medications for the treatment of PD (e.g., carbidopa/levodopa, pramipexole, ropinirole, benztropine, etc.).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
PD (Initial, reauth): 12 months

OTHER CRITERIA
PD (Reauth): Patient is benefiting from therapy (eg, patient had an improvement in motor function).
**ARANESP**

**MEDICATION(S)**
ARANESP 10 MCG/0.4 ML SYRINGE, ARANESP 100 MCG/0.5 ML SYRINGE, ARANESP 100 MCG/ML VIAL, ARANESP 150 MCG/0.3 ML SYRINGE, ARANESP 200 MCG/0.4 ML SYRINGE, ARANESP 200 MCG/ML VIAL, ARANESP 25 MCG/0.42 ML SYRING, ARANESP 25 MCG/ML VIAL, ARANESP 300 MCG/0.6 ML SYRINGE, ARANESP 300 MCG/ML VIAL, ARANESP 40 MCG/0.4 ML SYRINGE, ARANESP 40 MCG/ML VIAL, ARANESP 500 MCG/1 ML SYRINGE, ARANESP 60 MCG/0.3 ML SYRINGE, ARANESP 60 MCG/ML VIAL

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: Patient is on dialysis, OR all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS. CKD (init, reauth), Chemo (init), MDS (init): Verify iron evaluation for adequate iron stores.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
CKD (Init): 6 mo. CKD (reauth): 12 mo. Chemo(init, reauth): 3 mo. MDS; (init) 3 mo (reauth) 12
OTHER CRITERIA
Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 mo is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dl or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%.
ARCALYST

MEDICATION(S)
ARCALYST

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cryopyrin-Associated Periodic Syndromes (CAPS) (Initial): Diagnosis of CAPS, including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS). The medication will not be used in combination with another biologic.

AGE RESTRICTION
CAPS (Initial): 12 years of age or older

PRESCRIBER RESTRICTION
CAPS (Initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist.

COVERAGE DURATION
CAPS (initial, reauth): 12 months

OTHER CRITERIA
CAPS (Reauth): Patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidence by one of the following: A) improvement in rash, fever, joint pain, headache, conjunctivitis, B) decreased number of disease flare days, C) normalization of inflammatory markers (CRP, ESR, SAA), D) corticosteroid dose reduction, OR E) improvement in MD global score or active joint count.
MEDICATION(S)
AUBAGIO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
AUSTEDO

MEDICATION(S)
AUSTEDO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chorea associated with Huntington's disease (initial): Diagnosis of Chorea associated with Huntington's disease.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with a neurologist

COVERAGE DURATION
initial: 3 months, Reauth: 12 months

OTHER CRITERIA
Chorea associated with Huntington's disease (reauth): Documentation of positive clinical response to therapy.
AVASTIN

**MEDICATION(S)**
AVASTIN

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
Non-Small Cell Lung Cancer: Excluded if squamous cell histology or history of hemoptysis.

**REQUIRED MEDICAL INFORMATION**
Colorectal Cancer: Diagnosis of metastatic colorectal cancer. Used in combination with one of the following: 5-fluorouracil (5-FU), or oxaliplatin, or capecitabine, or irinotecan, or CapeOx (capecitabine and oxaliplatin), or 5-FU/LV (fluorouracil and leucovorin), or Fluoropyrimidine (eg, capecitabine, floxuridine, fluorouracil)-irinotecan-based therapy, or Fluoropyrimidine (eg, capecitabine, floxuridine, fluorouracil)-oxaliplatin-based therapy. Non-Small Cell Lung Cancer (NSCLC): Diagnosis of unresectable locally advanced recurrent or metastatic NSCLC. Used in combination with paclitaxel and carboplatin. Performance status 0 to 1. Renal Cell Cancer: Diagnosis of metastatic renal cell cancer. Used in combination with interferon-alpha. Breast Cancer: Diagnosis of breast cancer. Used in combination with paclitaxel. Age-related Macular Degeneration (ARMD): Diagnosis of age-related macular degeneration. Macular Edema: Diagnosis of macular edema following retinal vein occlusion. Glioblastoma: Diagnosis of glioblastoma. Relapsed, refractory, or disease progression on one of the following: radiation therapy, temozolomide, nitrosurea, combination PCV, or platinum-based regimen. Cervical Cancer: Diagnosis of persistent, recurrent, or metastatic carcinoma of the cervix. Used in combination with one of the following: paclitaxel/cisplatin, or paclitaxel/topotecan.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
ARMD, Macular Edema: Prescribed or recommended by ophthalmologist. All other uses: Prescribed or recommended by hematologist or oncologist.

**COVERAGE DURATION**
NSCLC: 6 months. All other uses: 12 months.

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
OTHER CRITERIA
Approve for continuation of prior therapy.
BARACLUDE

MEDICATION(S)
BARArelude, ENTECAVIR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Active type B viral hepatitis, chronic. LFTs must be monitored

AGE RESTRICTION
Age greater than or equal to 2 years

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
BAVENCIO

MEDICATION(S)
BAVENCIO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Merkel cell carcinoma (MCC): Diagnosis of metastatic Merkel cell carcinoma.

AGE RESTRICTION
MCC: Patient is 12 years of age or older.

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
BELEODAQ

MEDICATION(S)
BELEODAQ

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. History of failure, contraindication, or intolerance to at least one prior therapy (e.g., conventional chemotherapy).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
BENLYSTA

MEDICATION(S)
BENLYSTA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Systemic lupus erythematosus (SLE) (init): Diagnosis of active SLE. Autoantibody positive (ie, anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL). Currently receiving at least one standard of care treatment for active SLE (eg, antimalarials [eg, Plaquenil (hydroxychloroquine)], corticosteroids [eg, prednisone], or immunosuppressants [eg, methotrexate, Imuran (azathioprine), CellCept (mycophenolate mofetil)]).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
SLE (init): Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION
SLE (init, reauth): 6 months

OTHER CRITERIA
SLE (reauth): Documentation of positive clinical response to Benlysta therapy
BERINERT

MEDICATION(S)
BERINERT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Firazyr, Kalbitor, or Ruconest).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
BOSULIF

MEDICATION(S)
BOSULIF 100 MG TABLET, BOSULIF 500 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic myelogenous leukemia (CML): Diagnosis of Philadelphia chromosome-positive (Ph+) CML AND one of the following: A) Ph+ CML with resistance, relapse, or inadequate response to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tasigna [nilotinib], Sprycel [dasatinib] AND Patient has received mutation testing AND does not have the T315I or V299L mutation OR B) Ph+ CML with intolerance to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tasigna [nilotinib], Sprycel [dasatinib]

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
BOTOX

MEDICATION(S)
BOTOX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cervical dystonia: (Init) Dx of CD. Hyperhidrosis (HH): (Init) Dx of primary axillary HH. Score of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS) or skin maceration with secondary infection. (Reauth) At least a 2-point improvement in HDSS. Migraine: (Init) Dx of chronic migraines (greater than or equal to 15 migraine headache days per month with headache lasting 4 hours a day or longer). (Reauth) Reduction in headache frequency and intensity. Submission of chart notes documenting decreased utilization of pain medications (eg, narcotic analgesics, NSAIDs) or triptans, or a reduction in the number of ER visits. Achalasia: (Init) High risk of complication from pneumatic dilation or surgical myotomy, or failure to prior pneumatic dilation or surgical myotomy, or prior dilation caused esophageal perforation, or patient has an epiphrenic diverticulum or hiatal hernia. (Reauth) Documentation of improvement or reduction in symptoms of achalasia (ie, dysphagia, regurgitation, chest pain). Anal Fissure (AF): (Init) Dx of chronic AF. At least 2 months of either nocturnal pain and bleeding or postdefecation pain. (Reauth) Incomplete healing of fissure or recurrence of fissure. Improved symptoms with prior treatment with Botox. Chronic Back Pain (CBP): (Init) Dx of low back pain lasting greater than or equal to six months. Urinary incont: (init) Neurogenic detrusor overactivity associated with a neurologic condition (eg, spinal cord injury [SCI], multiple sclerosis) or detrusor sphincter dyssynergia with SCI. OAB: (initial) Dx of OAB. One of the following symptoms: urge urinary incontinence, urgency, frequency.

AGE RESTRICTION
CBP, UI: 18 years or older. VII cranial nerve disorders: 12 years or older.

PRESCRIBER RESTRICTION
Migraine (Initial): Prescribed by a neurologist or pain specialist. CBP (Initial): Prescribed by a neurologist, neurosurgeon, orthopedist, or pain specialist. UI, OAB: Prescribed by a neurologist, neurosurgeon, or urologist.
COVERAGE DURATION
CD: 90 days (1 dose up to 300 units) CBP: 1 tx (series of injxs) UI: 3 mo (1 dose, 200 units) Other: 6 mo

OTHER CRITERIA
Neuromuscular Disorders: Strabismus and blepharospasm associated with dystonia, benign essential blepharospasm, synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration, spasmodic dysphonia, dynamic muscle contracture in pediatric cerebral palsy patients, treatment of muscle spasticity as a result of CNS disorder or CNS injury, oromandibular dystonia, focal hand dystonia including writer's cramp and musician's cramp, VII cranial nerve disorders (hemifacial spasms) HH: Failure, contraindication, or intolerance (F/C/I) to topical prescription strength drying agents [eg, Drysol, Hypercare, Xerac AC (aluminum chloride hexahydrate)]. Migraine: F/C/I to prophylactic therapy with at least two of the following agents, each given for a trial of at least two months: antidepressants [eg, Effexor (venlafaxine)], antiepileptics [eg, Depakote/Depakote ER (divalproex sodium), Topamax (topiramate)], beta-blockers [eg, Inderal (propranolol), timolol, Toprol XL (metoprolol)]
CABOMETYX

MEDICATION(S)
CABOMETYX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Renal cell carcinoma (RCC): Diagnosis of RCC. History of failure, contraindication, or intolerance to at least one prior anti-angiogenic therapy [eg, Inlyta (axitinib), Votrient (pazopanib), Nexavar (sorafenib), Sutent (sunitinib)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RCC: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
CAPRELSA

MEDICATION(S)
CAPRELSA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Thyroid Cancer: Diagnosis of medullary thyroid cancer (MTC), and disease is one of the following: A) unresectable, locally advanced, or B) metastatic. One of the following: patient has symptomatic disease or patient has progressive disease.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with oncologist or endocrinologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
CARBAGLU

MEDICATION(S)
CARBAGLU

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Covered indications include the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency both as an adjunctive therapy for the treatment of acute hyperammonemia and as maintenance therapy for chronic hyperammonemia. Obtain baseline ammonia levels prior to treatment initiation and continue to monitor during treatment. Lab values or chart notes confirming deficiency of the hepatic enzyme N-acetylglutamate synthase.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Medication must be prescribed by an endocrinologist, geneticist, metabolic specialist or other prescriber with experience in N-acetylglutamate synthase deficiency.

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
CAYSTON

MEDICATION(S)
CAYSTON

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cystic fibrosis (CF) (Initial, Reauth): Diagnosis of CF AND Patient has evidence of Pseudomonas aeruginosa in the lungs

AGE RESTRICTION
CF (Initial): 7 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
CF (Initial, reauth): 12 months

OTHER CRITERIA
CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations)
CERDELGA

MEDICATION(S)
CERDELGA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Gaucher disease (Initial): Diagnosis of Gaucher disease type 1. Patient is an extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) of cytochrome P450 enzyme (CYP) 2D6 as detected by an FDA-cleared test.

AGE RESTRICTION
Gaucher disease (initial): 18 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Gaucher disease (initial, reauth): 12 months

OTHER CRITERIA
Gaucher disease (Reauth): Patients condition has not progressed, as defined by ALL of the following: A) Hemoglobin level decreased greater than 1.5 g/dL from baseline, AND B) Platelet count decreased greater than 25% from baseline, AND C) Spleen volume increased greater than 25% from baseline, AND D) Liver volume increased greater than 20% from baseline.
CEREZYME

MEDICATION(S)
CEREZYME

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Gaucher disease: Diagnosis of Type 1 Gaucher disease. Patient has evidence of symptomatic disease (eg, moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Gaucher disease: 12 months

OTHER CRITERIA
N/A
CHENODAL

MEDICATION(S)
CHENODAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of radiolucent stones in well-opacifying gallbladders. Patient is ineligible for surgery due to systemic disease or age.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Dosing: 13 to 16 mg/kg/day in two divided doses, starting with 250 mg twice daily the first two weeks and increasing by 250 mg/day each week thereafter until the recommended or maximum tolerated dose is reached.
CHOLBAM

MEDICATION(S)
CHOLBAM

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Bile acid synthesis disorders due to single enzyme defects (BAS) (initial): diagnosis of a bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorders (PD) (initial): All of the following: 1) diagnosis of peroxisomal disorder, 2) patient exhibits at least one of the following: a) liver disease (eg, jaundice, elevated serum transaminases), OR b) steatorrhea, OR c) complications from decreased fat-soluble vitamin absorption (eg, poor growth), AND 3) Cholbam will be used as an adjunctive treatment.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses (initial): Prescribed by a hepatologist, medical geneticist, pediatric gastroenterologist, OR other specialist that treats inborn errors of metabolism.

COVERAGE DURATION
All uses (initial, reauth): 12 months

OTHER CRITERIA
All uses (reauth): documentation of positive clinical response to Cholbam therapy
CIALIS

MEDICATION(S)
CIALIS 2.5 MG TABLET, CIALIS 5 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
Concurrent use of nitrates.

REQUIRED MEDICAL INFORMATION
Diagnosis of benign prostatic hyperplasia (BPH). Patient has experienced intolerance to or treatment failure with an alpha-blocker (e.g., doxazosin, prazosin, tamsulosin) or a 5-alpha reductase inhibitor (e.g., dutasteride, finasteride).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
CIMZIA

MEDICATION(S)
CIMZIA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA, initial): Diagnosis (dx) of moderately to severely active RA. Crohn's Disease (CD, initial): Dx of moderately to severely active CD. History (Hx) of failure, contraindication, or intolerance (F/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), Azathioprine (Imuran), Corticosteroid (eg, prednisone, methylprednisolone), Methotrexate (Rheumatrex, Trexall). Hx of F/C/I to Humira OR for continuation of prior Cimzia therapy. Psoriatic Arthritis (PsA, initial): Dx of active PsA. Ankylosing Spondylitis (AS, initial): Dx of active AS. RA, PsA, AS (initial): Hx of F/C/I to Enbrel and Humira OR for continuation of prior Cimzia therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
CD (init): Prescribed by or in consultation with a gastroenterologist. RA, AS (init): Prescribed by or in consultation with a rheumatologist. PsA (init): Prescribed by or in consultation with a dermatologist or rheumatologist.

COVERAGE DURATION

OTHER CRITERIA
Reauthorization (all indications): Documentation of positive clinical response to Cimzia therapy. All indications (initial and reauth): Patient is not receiving Cimzia in combination with either of the following: Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orenzia (abatacept)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].
CINRYZE

MEDICATION(S)
CINRYZE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prophylaxis of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks. For continuation of prior therapy or History of failure, contraindication, or intolerance of one of the following: 17-alpha alkylated androgen (eg, danazol, oxandroline) or antifibrinolytics (eg, tranexamic acid). Treatment of HAE attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Berinert, Firazyrr, Kalbitor, or Ruconest)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HAE (prophylaxis, treatment): Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
COMETRIQ

MEDICATION(S)
COMETRIQ

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Medullary thyroid cancer (MTC): Diagnosis of A) Metastatic MTC OR B) Both of the following: Unresectable locally advanced MTC AND patient has symptomatic or progressive disease. Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC and positive for RET gene rearrangements.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
MTC: Prescribed by or in consultation with oncologist/hematologist or Endocrinologist. NSCLC: Prescribed by or in consultation with an oncologist/hematologist.

COVERAGE DURATION
All uses: 12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
COSENTYX

MEDICATION(S)
COSENTYX (2 SYRINGES), COSENTYX PEN, COSENTYX PEN (2 PENS), COSENTYX SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: Failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab), OR for continuation of prior Cosentyx therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Cosentyx therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Cosentyx therapy. All indications (Initial, reauth): Patient is not receiving Cosentyx in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Cosentyx in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA or plaque psoriasis, Patient is not receiving Cosentyx in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Plaque psoriasis (Initial): Prescribed by or in consultation with a dermatologist. PsA (Initial): Prescribed by or in consultation with a rheumatologist or dermatologist. AS (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION
All indications (Initial, reauth): 12 months

OTHER CRITERIA
EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
All indications (Reauth): Documentation of positive clinical response to Cosentyx therapy.
COTELLIC

MEDICATION(S)
COTELLIC

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of unresectable or metastatic melanoma. Patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test (e.g., cobas 4800 BRAF V600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Used in combination with vemurafenib.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
CYRAMZA

MEDICATION(S)
CYRAMZA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Gastric cancer: All of the following: 1) diagnosis of one of the following: a) gastric adenocarcinoma, OR b) gastro-esophageal junction (GEJ) adenocarcinoma, AND 2) disease is one of the following: a) locally advanced, OR b) metastatic, AND 3) disease has progressed on or after one of the following first-line therapies: a) fluoropyrimidine-containing chemotherapy (eg, fluorouracil, capecitabine), OR b) platinum-containing chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Non-small cell lung cancer: All of the following: 1) diagnosis of metastatic non-small cell lung cancer, AND 2) used in combination with docetaxel, AND 3) disease has progressed on or after platinum-based chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Metastatic colorectal cancer (mCRC): 1) Diagnosis of metastatic CRC AND 2) Patient had disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
DAKLINZA

MEDICATION(S)
DAKLINZA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Criteria will be applied consistent with current AASLD/IDSA guideline. For genotype 1, ONE of the following: 1) Patient has a contraindication or intolerance to Harvoni or Zepatier OR 2) For continuation of prior Daklinza therapy. For genotype 3 patients with cirrhosis: patient is ineligible for treatment with peginterferon alfa confirmed by medical record documentation (eg, chart note, laboratory values) of ONE of the following: intolerance to interferon, autoimmune hepatitis or other autoimmune disorders, hypersensitivity to peginterferon or any of its components, major uncontrolled depressive illness, baseline neutrophil count below 1500/uL, baseline platelet count below 90,000/uL, baseline hemoglobin below 10 g/dL, history of preexisting cardiac disease, or decompensated hepatic disease. All: One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) OR 2) patient has failed prior therapy with an NS5A-containing regimen AND submission of medical records (eg, chart notes) documenting that the patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays. All: One of the following: 1) requested daily dosage is less than 90 mg OR 2) both of the following: requested daily dosage is equal to 90 mg and patient is concomitantly receiving a moderate CYP3A inducer (eg, bosentan, dexamethasone, efavirenz, etravirine, modafinil).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
DALIRESP

MEDICATION(S)
DALIRESP

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic Obstructive Pulmonary Disease (COPD): (Initial) Diagnosis of severe COPD. Patient has chronic bronchitis. Failure/contraindication/intolerance to two prior therapies for COPD.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
COPD (init, reauth): 12 months

OTHER CRITERIA
COPD (reauth): Documentation of positive clinical response to Daliresp therapy.
**MEDICATION(S)**
DARZALEX

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Multiple Myeloma (MM): Diagnosis of MM. Patient has received at least three prior treatment regimens which included both a proteasome inhibitor (eg, bortezomib [Velcade] and an immunomodulatory agent (eg, lenalidomide [Revlimid], thalidomide [Thalomid]) or patient is double-refractory to a proteasome inhibitor and an immunomodulatory agent.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with an oncologist/hematologist

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Approve for continuation of prior therapy
DEFERASIROX

**MEDICATION(S)**
EXJADE, JADENU, JADENU SPRINKLE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Chronic Iron Overload Due to Blood Transfusions (Initial): Diagnosis of chronic iron overload due to blood transfusions (transfusional hemosiderosis). Patient has a baseline ferritin level more than 1,000 mcg/L. Patient has required the transfusion of at least 100 mL/kg packed red blood cells. Myelodysplastic Syndrome (MDS) (Initial): Diagnosis of MDS. Patient has Low or Intermediate-1 disease or is a potential transplant patient. Patient has received more than 20 red blood cell transfusions. Chronic iron overload due to non-transfusion-dependent thalassemia (NTDT) (Initial): Diagnosis of chronic iron overload due to NTDT. Liver iron concentration (LIC) 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) or higher. Serum ferritin level greater than 300 mcg/L.

**AGE RESTRICTION**
Iron Overload Due to Blood Transfusions (initial): 2 years of age or older. NTDT (initial): 10 years of age or older

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
Iron Overload Due to Blood Transfusions, MDS (initial, reauth): 12 mo. NTDT (initial, reauth): 6mo.

**OTHER CRITERIA**
Iron Overload Due to Blood Transfusions, MDS (Reauth): Patient experienced a reduction from baseline in serum ferritin level or LIC. NTDT (Reauth): Patient has LIC 3 mg Fe/g dw or higher. Patient experienced a reduction from baseline in serum ferritin level or LIC.
**DUPIXENT**

**MEDICATION(S)**
DUPIXENT

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Atopic dermatitis (initial): Diagnosis of moderate to severe atopic dermatitis. Trial and failure, contraindication, or intolerance to one medium to high potency topical corticosteroid. One of the following: A) Trial and failure or intolerance to Elidel (pimecrolimus) topical cream, unless the patient is not a candidate for Elidel therapy (e.g., immunocompromised, severe atopic dermatitis), B) Trial and failure or intolerance to tacrolimus topical ointment, unless the patient is not a candidate for tacrolimus ointment therapy (e.g., immunocompromised).

**AGE RESTRICTION**
Initial: Age 18 years of age or older

**PRESCRIBER RESTRICTION**
Initial: Prescribed by or in consultation with one of the following: dermatologist, allergist/immunologist.

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Atopic dermatitis (reauth): Documentation of a positive clinical response to Dupixent therapy (e.g., reduction in body surface area involvement, reduction in pruritus severity)
EGRIFTA

MEDICATION(S)
EGRIFTA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
HIV-associated lipodystrophy (initial): All of the following: 1) diagnosis of HIV-associated lipodystrophy, 2) one of the following: a) waist-circumference of greater than or equal to 95 cm (37.4 inches) in men, OR b) waist-circumference of greater than or equal to 94 cm (37 inches) for women, 3) one of the following: a) Waist-to-hip ratio of greater than or equal to 0.94 for men, OR b) waist-to-hip ratio of greater than or equal to 0.88 for women, 4) body mass index (BMI) greater than 20 kg/m^2, AND 5) fasting blood glucose (FBG) levels less than or equal to 150 mg/dL (8.33 mmol/L), AND 6) patient has been on a stable regimen of antiretrovirals (eg, NRTIs, NNRTI, Protease Inhibitors, Integrase Inhibitors) for at least 8 weeks.

AGE RESTRICTION
(Initial): 18 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
(initial, reauth): 6 months

OTHER CRITERIA
(reauth): documentation of clinical improvement (eg, improvement in visceral adipose tissue [VAT], decrease in waist circumference, belly appearance, etc) while on Egrifta therapy.
ELAPRASE

MEDICATION(S)
ELAPRASE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of Hunter Syndrome (Mucopolysaccharidosis II (MPS II))

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
MEDICATION(S)
ELIGARD

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
EMFLAZA

MEDICATION(S)
EMFLAZA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Initial: Diagnosis of Duchenne muscular dystrophy (DMD). Patient has received genetic testing for a mutation of the dystrophin gene. One of the following: A) Documentation of a confirmed mutation of the dystrophin gene or B) Muscle biopsy confirmed an absence of dystrophin protein. Patient has had a trial and failure or intolerance to prednisone. Emflaza dose will not exceed 0.9 milligrams per kilogram of body weight once daily.

AGE RESTRICTION
Initial: Patient is 5 years of age or older

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with a neurologist who has experience treating children

COVERAGE DURATION
12 months

OTHER CRITERIA
(Reauth): Patient has experienced a benefit from therapy (e.g., improvement or preservation of muscle strength)
EMPLICITI

MEDICATION(S)
EMPLICITI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple myeloma: Diagnosis of multiple myeloma. Patient has received at least one prior Velcade (bortezomib)-containing regimen for multiple myeloma. Used in combination with Revlimid (lenalidomide) and dexamethasone.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ENBREL

MEDICATION(S)
ENBREL 25 MG KIT, ENBREL 25 MG/0.5 ML SYRINGE, ENBREL 50 MG/ML SURECLICK SYR, ENBREL 50 MG/ML SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Failure, contraindication, or intolerance to one disease-modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of moderately to severely active pJIA. Failure, contraindication, or intolerance to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. Failure, contraindication, or intolerance to two NSAIDs. All indications (Initial, reauth): Patient is not receiving Enbrel in combination with a biologic DMARD [eg, Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]. Patient is not receiving Enbrel in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA (Initial), PJIA (Initial), AS (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a rheumatologist or dermatologist. Plaque Psoriasis (Initial): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION
All indications (Initial, reauth): 12 months

OTHER CRITERIA
All indications (Reauth): Documentation of positive clinical response to Enbrel therapy.
EPCLUSA

MEDICATION(S)
EPCLUSA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Criteria will be applied consistent with current AASLD/IDSA guideline. Submission of medical records (e.g., chart notes, laboratory values) documenting a diagnosis of chronic hepatitis C virus. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral agent [e.g., Sovaldi (sofosbuvir), Olysio (simeprevir)]. One of the following: a) genotypes 2, 3, 5, or 6, or b) genotypes 1 or 4: history of failure, contraindication, or intolerance to Harvoni and Zepatier or, for patients with decompensated cirrhosis, history of failure, contraindication, or intolerance to Harvoni, or c) patient is currently on Epclusa therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hepatologist, gastroenterologist, infectious disease specialist, or HIV specialist certified through the American Academy of HIV Medicine.

COVERAGE DURATION
12 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.

OTHER CRITERIA
N/A
EPOETIN ALFA

MEDICATION(S)
EPOGEN 20,000 UNITS/2 ML VIAL, PROCRIT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: Patient is on dialysis, OR all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with HIV (Initial): Anemia by lab values (Hgb less than 12 g/dL or Hct less than 36%) collected within 30 days of request. Serum erythropoietin level less than or equal to 500 mU/mL. Receiving zidovudine therapy or dx of HIV. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 mos, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Preoperative for reduction of allogeneic blood transfusion: Patient is scheduled to undergo elective, non-cardiac, non-vascular surgery. Hgb is greater than 10 to less than or equal to 13 g/dL. Patient is at high risk for perioperative transfusions. Patient is unwilling or unable to donate autologous blood pre-operatively. Anemia in hepatitis C virus (HCV)-infected pts due to ribavirin in combination with interferon or peg-interferon (Initial): Dx of HCV infection. Anemia by labs (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. Patient is receiving ribavirin and one of the following: interferon alfa or peginterferon alfa. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
COVERED DURATION

OTHER CRITERIA
Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 months is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. HIV (Reauth): Most recent or avg Hct over 3 months is below 36% or most recent or avg Hgb over 3 months is below 12 g/dL. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dL or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. HCV (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. If patient has demonstrated response to therapy, authorization will be issued for the full course of ribavirin therapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%. CKD (init, reauth), HIV (init), Chemo (init), Preop, MDS (init), HCV (init): Verify iron evaluation for adequate iron stores.
ERBITUX

MEDICATION(S)
ERBITUX 100 MG/50 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Head and Neck Cancer: Diagnosis of locally or regionally advanced squamous cell head and neck cancer and used in combination with radiation therapy, or diagnosis of recurrent or metastatic squamous cell head and neck cancer and 1 of the following: failure of platinum-based chemotherapy, or used in combination with 1 of the following: cisplatin (Platinol AQ), carboplatin (Paraplatin), cisplatin (Platinol AQ) plus 5-FU (Adrucil), or carboplatin (Paraplatin) plus 5-FU (Adrucil). Colorectal Cancer: Diagnosis of metastatic carcinoma of the colon or rectum. One of the following: Used in combination with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan), OR failure or intolerance to irinotecan-based chemotherapy, oxaliplatin-based chemotherapy, or intensive therapy (eg, FOLFOX or FOLFIRI), OR used as monotherapy in patients not appropriate for intensive therapy. Tumor expresses wild-type KRAS gene and wild type NRAS gene. Non-Small Cell Lung Cancer (NSCLC): Diagnosis of recurrent or metastatic NSCLC stage IIIB or IV. One of the following: Used in combination with vinorelbine (Navelbine) and cisplatin (Platinol AQ), OR used as a single-agent for continuation maintenance therapy and Erbitux was given first-line with chemotherapy. ECOG performance status 0-2. Epidermal growth factor receptor (EGFR) expression by immunohistochemistry.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months.

OTHER CRITERIA
EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
Subject to Part B vs. Part D review. Approve for continuation of prior therapy.
ERIVEDGE

MEDICATION(S)
ERIVEDGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Basal cell carcinoma: One of the following: A) Diagnosis of metastatic basal cell carcinoma OR B) Both of the following: 1) Diagnosis of locally advanced basal cell carcinoma AND 2) One of the following: a) Disease recurred following surgery or b) Patient is not a candidate for surgery and radiation.

AGE RESTRICTION
18 years of age or older

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ESBRIET

MEDICATION(S)
ESBRIET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity), AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Ofev (nintedanib).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
IPF (initial): Prescribed by a pulmonologist

COVERAGE DURATION
initial, reauth: 12 months

OTHER CRITERIA
IPF (reauth): Documentation of positive clinical response to Esbriet therapy
**FABRAZYME**

**MEDICATION(S)**
FABRAZYME

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Fabry Disease: Diagnosis of Fabry disease.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
Fabry Disease: 12 months

**OTHER CRITERIA**
N/A
FARYDAK

MEDICATION(S)
FARYDAK

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Myeloma (MM): Diagnosis of MM. Used in combination with both of the following: Velcade (bortezomib) and dexamethasone. Patient has received at least two prior treatment regimens which included both of the following: Velcade (bortezomib) and an immunomodulatory agent [eg, Revlimid (lenalidomide), Thalomid (thalidomide)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
FENTANYL

**MEDICATION(S)**
ABSTRAL, FENTANYL CIT OTFC 1,200 MCG, FENTANYL CIT OTFC 1,600 MCG, FENTANYL CITRATE OTFC 200 MCG, FENTANYL CITRATE OTFC 400 MCG, FENTANYL CITRATE OTFC 600 MCG, FENTANYL CITRATE OTFC 800 MCG

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
For the management of breakthrough cancer pain. Patient is currently taking a long-acting opioid around the clock for cancer pain. Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids: Morphine sulfate at doses of greater than or equal to 60 mg/day, Fentanyl transdermal patch at doses greater than or equal to 25 mcg/hr, Oxycodone at a dose of greater than or equal to 30 mg/day, Oral hydromorphone at a dose of greater than or equal to 8 mg/day, Oral oxymorphone at a dose of greater than or equal to 25 mg/day, or an alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 mg/day).

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
N/A
FERRIPROX

MEDICATION(S)
FERRIPROX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Transfusional iron overload due to thalassemia syndromes (Initial): Patient has a diagnosis of transfusional iron overload due to thalassemia syndromes. Absolute neutrophil count (ANC) greater than 1.5 x 10^9/L. One of the following: A) Patient has failed prior chelation therapy (e.g., Exjade) [failure defined as serum ferritin greater than 2,500 mcg/L] OR B) Patient has a contraindication or intolerance to Desferal (deferexamine) or Exjade (deferasirox).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All uses (initial, reauth): 12 months

OTHER CRITERIA
All uses (reauth): Patient has experienced greater than or equal to 20% decline in serum ferritin levels from baseline. ANC greater than 0.5 x 10^9/L.
FIRAZYR

MEDICATION(S)
FIRAZYR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Berinert, Kalbitor, or Ruconest).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
FIRMAGON

MEDICATION(S)
FIRMAGON

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of advanced or metastatic prostate cancer.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
FLECTOR

MEDICATION(S)
FLECTOR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
History of severe allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory (NSAIDs), including urticaria and asthma (aspirin-sensitive asthma).

REQUIRED MEDICAL INFORMATION
Pain: Diagnosis of acute, localized pain due to minor strains, sprains and contusions. Diclofenac will not be used in the treatment of peri-operative pain in the setting of coronary artery bypass graft surgery or used on non-intact or damaged skin. Patient meets one of the following: 1) Treatment failure with at least two prescription strength oral non-steroidal anti-inflammatory drugs (NSAIDs). OR 2) Documented swallowing disorder. OR 3) History of peptic ulcer disease/gastrointestinal bleed. OR 4) Patient is older than 65 years of age with one additional risk factor for gastrointestinal adverse events (e.g. use of anticoagulants, chronic corticosteroids).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
3 months

OTHER CRITERIA
N/A
FOLOTYN

MEDICATION(S)
FOLOTYN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Peripheral T-cell lymphoma: with diagnosis of relapsed or refractory PTCL.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
FONDAPARINUX

MEDICATION(S)
FONDAPARINUX SODIUM

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. Treatment of DVT or acute pulmonary embolism when administered in conjunction with warfarin.

AGE RESTRICTION
Patient must be at least 18 years old

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Hip fracture surgery prophylaxis: 60 days  All other indications: 14 days

OTHER CRITERIA
Exclude for pts with Active major bleeding, Bacterial endocarditis, Body weight less than 50 kg (venous thromboembolism prophylaxis only), Fondaparinux-related thrombocytopenia, Severe renal impairment (creatinine clearance less than 30 milliliters/minute)
FORTEO

MEDICATION(S)
FORTEO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Postmenopausal Osteoporosis or men with primary or hypogonadal osteoporosis: Diagnosis of osteoporosis AND One of the following: A) Bone mineral density (BMD) T score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) or B) Both of the following: 1) BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and 2) either a history of one of the following fractures (fx) resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) OR failure, contraindication, or intolerance (F/C/I) to one bisphosphonate (BP) [e.g., Fosamax (alendronate)] or C) Both of the following: History of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) and F/C/I to one BP [e.g., Fosamax (alendronate)]. Glucocorticoid-Induced Osteoporosis: Dx of glucocorticoid-induced osteoporosis. History of prednisone or equivalent at a dose of 5mg/day or greater for 3 months or greater.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All indications: 12 months, max 2 years of therapy.

OTHER CRITERIA
All indications: Treatment duration has not exceeded a total of 24 months during the patient’s
lifetime. Glucocorticoid-Induced Osteoporosis: One of the following: A) BMD T score of -2.0 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) or B) Both of the following: 1) BMD T score between -1.0 and -2.0 (BMD T-score greater than -2.0 and less than or equal to -1.0) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and 2) either history of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) or F/C/I to one BP [e.g., Fosamax (alendronate)] or C) Both of the following: 1) history of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) and 2) F/C/I to one BP [e.g., Fosamax (alendronate)].
GAMASTAN S/D

MEDICATION(S)
GAMASTAN S-D

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication).

REQUIRED MEDICAL INFORMATION
Immune globulin is being used intramuscularly. The immune globulin will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. Patient requires immunization for hepatitis A, measles, rubella, or varicella.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
3 months (Approve one dose only)

OTHER CRITERIA
Subject to Part B vs D review.
GATTEX

MEDICATION(S)
GATTEX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Short Bowel Syndrome (SBS) (Initial) Diagnosis of SBS. Patient is dependent on parenteral nutrition/intravenous (PN/IV) support for at least 12 consecutive months.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
SBS (Init): 6 months. SBS (Reauth): 12 months.

OTHER CRITERIA
SBS (Reauth): Documentation of positive clinical response to Gattex therapy.
GILENYA

MEDICATION(S)
GILENYA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
GILOTRIF

**MEDICATION(S)**
GILOTRIF

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Non-small cell lung cancer (NSCLC): A) Diagnosis of advanced or metastatic (stage IIIB or IV) NSCLC AND B) One of the following: 1) Both fo the following: a) Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 (L858R) substitution, exon 18 (G719X, G719) or exon 20 (S7681) mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND b) GILOTRIF will be used as first-line treatment, OR 2) All of the following: a) disease progressed after platinum-based chemotherapy and b) squamous NSCLC.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with an oncologist

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Approve for continuation of prior therapy.
GLATIRAMER ACETATE

MEDICATION(S)
COPAXONE 40 MG/ML SYRINGE, GLATOPA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
GLEEVEC

MEDICATION(S)
GLEEVEC, IMATINIB MESYLATE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
For adults 18 years of age or older, One of the following: A) Diagnosis of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) AND Patient is found to be Ph+ or BCR-ABL positive as detected by bone marrow cytogenetics, FISH or PCR OR B) Ph+ acute lymphoblastic leukemia (ALL) OR C) Gastrointestinal stromal tumor (GIST) AND one of the following: 1) Patient has documented c-KIT (CD117) positive unresectable or metastatic malignant GIST, OR 2) Patient had resection of c-KIT (CD117) positive GIST and imatinib will be used as adjuvant therapy OR D) Dermatofibrosarcoma protuberans that is unresectable, recurrent, or metastatic OR E) Hypereosinophilic syndrome or chronic eosinophilic leukemia OR F) Myelodysplastic syndrome (MDS) or myeloproliferative disease associated with platelet-derived growth factor receptor gene re-arrangements OR G) Aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknown. For Pediatric patients younger than 18 years of age, One of the following: A) Diagnosis of Ph+ CML that is newly diagnosed in the chronic phase OR B) Diagnosis of newly diagnosed Ph+ALL.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION
All uses: 12 months

OTHER CRITERIA
All uses: Approve for continuation of prior therapy.
GROWTH HORMONE

MEDICATION(S)
GENOTROPIN, HUMATROPE, NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NUTROPIN AQ, NUTROPIN AQ NUSPIN, OMNITROPE, SAIZEN, ZOMACTON

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
PGHD(initial): less than 4mo w/GD, or hx neonatal hypoglycemia assoc w/pituitary dz, or panhypopituitarism dx, or all of the following: PGHD dx [confrmd by ht (utilizing age and gender growth charts related to ht) documented(doc) by ht more than 2.0SD below midparental ht or more than 2.25SD below population(pop) mean (below 1.2 percentile for age and gender), or growth velocity more than 2SD below mean for age and gender, or delayed skeletal maturation more than 2SD below mean for age and gender (eg, delayed more than 2yrs compared w/chronological age)], and ped GH dosing used as defined by PI. PWS(reauth): evidence of positive response to tx(eg, incr in total LBM, decr in fat mass), or ht incr at least 2cm/yr over previous yr of tx (doc by previous ht and date and current ht and date) and expctd adult ht not attained and docs of expctd adult ht goal. GFSGA(initial): SGA dx based on catchup growth failure in 1st 24mo of life using 0-36mo growth chart confirmed by birth wt or length below 3rd percentile for gestational age (more than 2SD below pop mean) and ht remains at or below 3rd percentile (more than 2SD below pop mean). TS, NS(initial): ped growth failure dx assoc w/TS w/doc female w/bone age less than 14yrs, or NS and ht below 5th percentile on growth charts for age and gender. SHOX(initial): ped growth failure dx assoc w/CRI. ISS(initial): ISS dx, diagnostic eval excluded other causes assoc w/short stature(eg GHD, chronic renal insufficiency), doc ht at or below -2.25SD score below corresponding mean ht for age and gender, doc growth velocity less than 25th percentile for bone age. PGHD, NS, SHOX, GFCRI, ISS (initial): doc male w/bone age less than 16yrs or female w/bone age less than 14yrs. PGHD, GFSGA, TS/NS, SHOX, GFCRI, ISS (reauth): ht incr of at least 2 cm/yr over previous yr of tx (doc by previous ht and date and current ht and date) and expctd adult ht not attained and docs of expctd adult ht goal.

AGE RESTRICTION
N/A
PRESCRIBER RESTRICTION
PGHD, PWS, GFSGA, TS/NS, SHOX, AGHD, TPAP, IGHDA, ISS: prescribed by endocrinologist.
GFCRI: prescribed by endocrinologist or nephrologist

COVERAGE DURATION
All indications (initial, reauth): 12 months

OTHER CRITERIA
AGHD(initial): dx of AGHD as a result of clinical records supporting dx of childhood-onset GHD, or
adult-onset GHD w/clinical records doc hormone deficiency due to hypothalamic-pituitary dz from
organic or known causes (eg, damage from surgery, cranial irradiation, head trauma, subarachnoid
hemorrhage) and pt has 1 GH stim test (insulin tolerance test [ITT],
arginine/GHRH,glucagon,arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at
or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L
if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above
30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or doc deficiency of 3 anterior
pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IGF-1/somatomedinC below age and
gender adjusted nrml range as provided by physicians lab. AGHD(initial, reauth): not used in
combo w/aromatase inhibitors (eg, Arimidex[anastrozole], Femara[letrozole]), Androgens
(eg, Delagestrel[testosterone enanthate], Depo-testosterone[testosterone cypionate]), and adult
dosing utilized as defined by PI. AGHD, IGHDA(reauth): evidence of ongoing monitoring as
demonstrated by doc w/in past 12mo of IGF-1/somatomedinC level. TransitionPhaseAdolescent
Pts(TPAP)(initial): adult GH dosing used as defined by PI/AACE 2009 tx GL, attained expctd adult
ht or closed epiphyses on bone radiograph, and doc high risk of GHD due to GHD in childhood
(from embryopathic/congenital defects, genetic mutations, irreversible structural hypothalamic-
pituitary dz, panhypopituitarism, or deficiency of 3 anterior pituitary
hormones:ACTH,TSH,prolactin,FSH/LH), w/IGF-1/somatomedinC below age and gender adj nrml
range as provided by physicians lab, or pt does not have low IGF-1/somatomedinC and d/c GH tx
for at least 1mo, and pt has 1 GH stim test (ITT,GHRH+ARG,ARG,glucagon) after d/c of tx for at
least 1mo w/corresponding peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below
11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2,
or at or below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below
0.4mcg/L], or at low risk of severe GHD(eg d/t isolated and/or idiopathic GHD) and d/c GH tx for at
least 1mo, and pt has 1 GH stim test (ITT, GHRH+ARG, ARG, glucagon) after d/c of tx for at least
1mo w/corresponding peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below 11mcg/L
if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or
below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
0.4 mcg/L. TPAP(reauth): evidence of positive response to therapy (eg, incr in total lean body mass, exercise capacity or IGF-1 and IGFBP-3), and continued adult GH dosing used as defined by PI/AACE 2009 tx GL. IGHDA(initial): doc GHD by failure to produce peak serum GH greater than 5 mcg/L after 2 provocative pharmacol stim tests (insulin, L-ARG, glucagon).
HALAVEN

MEDICATION(S)
HALAVEN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast Cancer: Diagnosis of recurrent or metastatic breast cancer. Previous treatment with both of the following: one anthracycline [eg, doxorubicin, Ellence (epirubicin)] and one taxane [eg, paclitaxel, Taxotere (docetaxel)]. Liposarcoma: Diagnosis of unresectable or metastatic liposarcoma. Previous treatment with one anthracycline-containing regimen.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Uses: prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
HARVONI

MEDICATION(S)
HARVONI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND
B) Patient is not receiving Harvoni in combination with another HCV direct acting antiviral agent
[eg, Sovaldi (sofosbuvir), Olysio (simeprevir)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
12 to 24 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
HEPSERA

MEDICATION(S)
ADEFOVIR DIPIVOXIL, HEPSERA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The patient must have a diagnosis of chronic hepatitis B viral infection. Patients with lamivudine-resistant HBV: use adefovir in combination with lamivudine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
HIV antibody testing prior to initiation of therapy. Prior authorization requests shall not be granted for use in HIV (Human Immunodeficiency Virus).
HERCEPTIN

MEDICATION(S)
HERCEPTIN 440 MG VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. One of the following treatment regimens: a) As adjuvant treatment, b) metastatic disease and one of the following: 1) used in combination with a taxane (eg, docetaxel, paclitaxel), or 2) used as a single agent in a patient who has received one or more chemotherapy regimens for metastatic disease, or c) used in combination with Perjeta (pertuzumab). Gastric Cancer: Diagnosis of HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma (locally advanced, recurrent, or metastatic). Used in combination with one of the following treatment regimens: a) Adrucil (5-fluorouracil), or b) Platinol (cisplatin) and Xeloda (capecitabine).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
HETLIOZ

MEDICATION(S)
HETLIOZ

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-24-Hour Sleep-Wake Disorder (Non-24) (initial): Both of the following: 1) Diagnosis of non-24-hour sleep-wake disorder (also known as free-running disorder, free-running or non-entrained type circadian rhythm sleep disorder, or hypernychthemeral syndrome), AND 2) patient is totally blind (has no light perception).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Non-24 (initial): Prescribed by or in consultation with a specialist in sleep disorders or neurologist.

COVERAGE DURATION
Non-24 (initial): 6 mo. (reauth): 12 mo

OTHER CRITERIA
Non-24 (reauth): Documentation of positive clinical response to Hetlioz therapy.
HRM - ANTIHISTAMINES

MEDICATION(S)
CYPROHEPTADINE HCL, PHENADOZ 12.5 MG SUPPOSITORY, PROMETHAZINE HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
HRM - ANTIHYPERTENSIVE AGENTS

MEDICATION(S)
GUANFACINE HCL, GUANFACINE HCL ER, METHYLDOPA, RESERPINE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (Low dose thiazide or a second generation calcium channel blocker OR ACE inhibitor, ARB, beta-blocker or combination product based on specific chronic conditions) AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
HRM - ANTIPARKINSON AGENTS

MEDICATION(S)
BENZTROPINE MES 0.5 MG TAB, BENZTROPINE MES 1 MG TABLET, BENZTROPINE MES 2 MG TABLET, TRIHEXYPHENIDYL HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
HRM - ANTIPSYCHOTICS

MEDICATION(S)
THIORIDAZINE HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (haloperidol, atypical antipsychotic) AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Applies to New Starts only.
HRM - CARDIOVASCULAR, ANTI-ARRHYTHMICS

**MEDICATION(S)**
DISOPYRAMIDE PHOSPHATE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

**AGE RESTRICTION**
PA applies to patients 65 years or older

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
N/A
HRM - CNS, OTHER

MEDICATION(S)
MEPROBAMATE 400 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
HRM - DEMENTIA AGENTS

MEDICATION(S)
ERGOLOID MESYLATES

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (donepezil, galantamine, rivastigmine, memantine) AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
MEDICATION(S)
MEGESTROL ACETATE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Applies to New Starts only.
HRM - PAIN MEDICATIONS

MEDICATION(S)
KETOROLAC 15 MG/ML VIAL, KETOROLAC 30 MG/ML VIAL, MEPERIDINE 100 MG/ML VIAL, MEPERIDINE 25 MG/ML VIAL, MEPERIDINE 50 MG/ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (Mild pain: acetaminophen, codeine. Moderate to severe pain: short-term NSAIDs, tramadol, tramadol/APAP, morphine sulfate, hydrocodone/APAP, oxycodone, oxycodone/APAP, fentanyl) AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
HRM - TERTIARY TCA

MEDICATION(S)
AMITRIPTYLINE HCL, CLOMIPRAMINE HCL, DOXEPIN 10 MG CAPSULE, DOXEPIN 10 MG/ML ORAL CONC, DOXEPIN 100 MG CAPSULE, DOXEPIN 150 MG CAPSULE, DOXEPIN 25 MG CAPSULE, DOXEPIN 50 MG CAPSULE, DOXEPIN 75 MG CAPSULE, IMIPRAMINE HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative AND prescriber attestation that benefit outweighs risk of drugs found to be high risk medications for beneficiaries age 65 and older.

AGE RESTRICTION
PA applies to patients 65 years or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Applies to New Starts only.
HUMIRA

MEDICATION(S)
HUMIRA, HUMIRA PEDIATRIC CROHN’S, HUMIRA PEN, HUMIRA PEN CROHN-UC-HS STARTER, HUMIRA PEN PSORIASIS-UVEITIS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Failure, contraindication, or intolerance to one disease modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. Failure, contraindication, or intolerance to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. Failure, contraindication, or intolerance to two NSAIDs. Crohn's Disease (CD) (Initial): Diagnosis of moderately to severely active CD. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall), or failure (ie, lost response) or intolerance to Remicade (infliximab). Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate (eg, mesalamine (Asacol, Pentasa, Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)). Hidradenitis suppurativa (Initial): Diagnosis of moderate to severe hidradenitis suppurativa (ie, Hurley Stage II or III). All indications (initial, reauth): Patient is not receiving Humira in combination with a biologic DMARD [eg, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]. Patient is not receiving Humira in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION
N/A
PRESCRIBER RESTRICTION
RA, AS, JIA (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a dermatologist or rheumatologist. Plaque Psoriasis, HS (Initial): Prescribed by or in consultation with a dermatologist. CD, UC (Initial): Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION
UC (Initial): 12 wks. UC (reauth): 12 mo. All other indications (initial, reauth): 12 mo.

OTHER CRITERIA
RA, JIA, PsA, Plaque psoriasis, AS, CD, Hidradenitis suppurativa (HS) (Reauth): Documentation of positive clinical response to Humira therapy. UC (Reauth): For patients who initiated Humira therapy within the past 12 weeks: Documentation of clinical remission or significant clinical benefit by eight weeks (Day 57) of therapy OR For patients who have been maintained on Humira therapy for longer than 12 weeks: Documentation of positive clinical response to Humira therapy.
IBRANCE

MEDICATION(S)
IBRANCE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast Cancer: Diagnosis of breast cancer. Disease is a) locally advanced or metastatic, b) estrogen-receptor (ER)-positive, and c) human epidermal growth factor receptor 2 (HER2)-negative. One of the following: a) used in combination with Femara (letrozole) and patient is a postmenopausal woman, OR b) all of the following: used in combination with Faslodex (fulvestrant), disease has progressed following endocrine therapy, and one of the following: 1) patient is a postmenopausal woman OR 2) both of the following: patient is a premenopausal or perimenopausal woman and patient is receiving a luteinizing hormone-releasing hormone (LHRH) agonist [eg, Zoladex (goserelin)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 Months

OTHER CRITERIA
Approve for continuation of prior therapy.
**ICLUSIG**

**MEDICATION(S)**
ICLUSIG

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Chronic myelogenous leukemia: Diagnosis of chronic myelogenous leukemia AND One of the following: A) History of failure, resistance, relapse, contraindication, or intolerance to at least TWO other tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL, TASIGNA, and BOSULIF), or B) Patient has the T315I mutation. Acute Lymphoblastic Leukemia: Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) AND One of the following: A) History of failure, resistance relapse, contraindication, or intolerance to at least TWO other FDA-approved tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL), or B) Patient has the T315I mutation.

**AGE RESTRICTION**
All Uses: 18 years of age or older

**PRESCRIBER RESTRICTION**
All Uses: Prescribed by or in consultation with an oncologist or hematologist

**COVERAGE DURATION**
All uses: 12 months

**OTHER CRITERIA**
All uses: Approve for continuation of prior therapy.
IDHIFA

MEDICATION(S)
IDHIFA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acute Myeloid Leukemia (AML): Diagnosis of AML. Disease is relapsed or refractory. Patient has an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH2 assay) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ILARIS

MEDICATION(S)
ILARIS 180 MG VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cryopyrin-Associated Periodic Syndromes (CAPS) (Initial): Diagnosis of CAPS, including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS) AND The medication will not be used in combination with another biologic agent. Systemic juvenile idiopathic arthritis (sJIA) (Initial): Diagnosis of active sJIA AND The medication will not be used in combination with another biologic

AGE RESTRICTION
CAPS (initial): 4 years of age or older. SJIA (initial): 2 years of age or older

PRESCRIBER RESTRICTION
CAPS (initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist

COVERAGE DURATION
All indications (initial, reauth): 12 months

OTHER CRITERIA
CAPS, SJIA (Reauth): Patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidence by one of the following: A) improvement in rash, fever, joint pain, headache, conjunctivitis, B) decreased number of disease flare days C) normalization of inflammatory markers (CRP, ESR, SAA), D) corticosteroid dose reduction or E) improvement in MD global score or active joint count.
IMBRUVICA

MEDICATION(S)
IMBRUVICA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Mantle cell lymphoma (MCL): Diagnosis of MCL AND patient has relapsed or is refractory to at least one prior therapy for the treatment of MCL. Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Waldenström’s macroglobulinemia: Diagnosis of Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma. Small lymphocytic lymphoma (SLL): Diagnosis of SLL. Marginal zone lymphoma (MZL): Diagnosis of MZL AND patient has received at least one prior anti-CD20-based therapy for MZL [e.g., Rituxan (rituximab), Zevalin (ibritumomab), Gazyva (obinutuzumab, etc.)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION
All Uses: 12 months

OTHER CRITERIA
All Uses: Approve for continuation of prior therapy.
IMFINZI

MEDICATION(S)
IMFINZI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Urothelial carcinoma: 1) Diagnosis of locally advanced or metastatic urothelial carcinoma AND 2) One of the following: a) Patient has experienced disease progression during or following platinum-containing chemotherapy OR b) Patient has experienced disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
INCRELEX

MEDICATION(S)
INCRELEX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Insulin-like Growth Factor-1 (IGF-1) deficiency (initial): Diagnosis of severe primary IGF-1 deficiency. Height standard deviation score of -3.0 or less. Basal IGF-1 standard deviation score of -3.0 or less. Normal or elevated growth hormone (GH). Documentation of open epiphyses on last bone radiograph. The patient will not be treated with concurrent GH therapy. GH gene deletion (initial): Diagnosis of GH gene deletion in patients who have developed neutralizing antibodies to GH. Documentation of open epiphyses on last bone radiograph. The patient will not be treated with concurrent GH therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with a pediatric endocrinologist

COVERAGE DURATION
Initial, reauth: 12 months

OTHER CRITERIA
(Reauth): Evidence of positive response to therapy.
INFLECTRA

MEDICATION(S)
INFLECTRA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (initial): Dx of moderately to severely active CD or FCD. Ulcerative colitis (UC) (initial): Dx of moderately to severely active UC. Rheumatoid arthritis (RA) (initial): Diagnosis (Dx) of moderately to severely active RA. Ankylosing spondylitis (AS) (initial): Dx of active AS. Psoriatic arthritis (PsA) (initial): Dx of active PsA. Plaque psoriasis (initial): Dx of chronic severe (ie, extensive and/or disabiling) plaque psoriasis. Reauthorization for all indications: Documentation of positive clinical response to infliximab therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA, AS: Prescribed or recommended by a rheumatologist. PsA: Prescribed or recommended by rheumatologist or dermatologist. Crohn’s Disease, Fistulizing Crohn’s Disease, UC: Prescribed or recommended by a gastroenterologist. Plaque Psoriasis: Prescribed or recommended by a dermatologist.

COVERAGE DURATION
All indications (initial, reauth): 12 months

OTHER CRITERIA
CD, FCD (initial): Failure, contraindication or intolerance to one of the following conventional therapies: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). History of failure, contraindication or intolerance to Remicade, unless already receiving Inflectra. UC (initial): Failure, contraindication or intolerance to one of the following conventional therapies: corticosteroids, aminosalicylate (eg,
mesalamine (Asacol/Pentasa/Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine/Sulfazine)], azathioprine (Imuran), 6-mercaptopurine (Purinethol). History of failure, contraindication or intolerance to Remicade, unless already receiving Inflectra. RA (initial): Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), or failure, contraindication or intolerance to methotrexate. AS (initial): Failure, contraindication or intolerance to two or more NSAIDs. History of failure, contraindication or intolerance to Remicade, unless already receiving Inflectra. All indications (Initial and re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].
INGREZZA

**MEDICATION(S)**
INGREZZA 40 MG CAPSULE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Tardive Dyskinesia (initial): Diagnosis of moderate to severe tardive dyskinesia. One of the following: a) patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication OR b) patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Initial: Prescribed by or in consultation with a neurologist or psychiatrist.

**COVERAGE DURATION**
Initial: 3 months, Reauth: 12 months

**OTHER CRITERIA**
Tardive Dyskinesia (reauth): Documentation of positive clinical response to Ingrezza therapy.
INLYTA

MEDICATION(S)
INLYTA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Renal cell cancer (RCC): Diagnosis of RCC. One of the following: (1) Relapse following surgical excision or (2) medically or surgically unresectable tumor and diagnosis of Stage IV disease. One of the following: (1) Patient with non-clear cell histology or (2) both of the following: patient has predominantly clear cell histology and history of failure, contraindication, or intolerance to one of the following: cytokine-based therapy [eg, IL-2], kinase inhibitor therapy [eg, Nexavar (sorafenib), Sutent (sunitinib), Votrient (pazopanib)], Avastin (bevacizumab) in combination with Interferon (IFN)-alfa therapy, mammalian target of rapamycin (mTOR) inhibitor therapy [eg, Torisel (temsirolimus)]

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
INTRON A

MEDICATION(S)
INTRON A

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Diagnosis of chronic hepatitis C, patient without decompensated liver disease, patient has not previously been treated with interferon, and one of the following - 1) used in combination with ribavirin or 2) contraindication or intolerance to ribavirin. Metastatic renal cell carcinoma (RCC): diagnosis of metastatic RCC, used in combination with Avastin (bevacizumab). Other: diagnosis of condylomata acuminata (genital or perianal), diagnosis of hairy cell leukemia, diagnosis of AIDS-related Kaposis sarcoma, diagnosis of malignant melanoma, diagnosis of Stage III or IV follicular Non-Hodgkins Lymphoma, as maintenance therapy for the treatment of multiple myeloma.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RCC: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
HepB, HepC: 48 wks. Condylomata acuminata (genital or perianal): 6 wks. Other: 12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
IRESSA

MEDICATION(S)
IRESSA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
MEDICATION(S)
ISTODAX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Patient has tried and had an inadequate response, intolerance or contraindication to at least one prior therapy (eg, retinoids, corticosteroids). Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. Patient has tried and had an inadequate response, intolerance or contraindication to at least one prior therapy (eg, conventional chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone), Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate and cytarabine).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
CTCL, PTCL: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
MEDICATION(S)
BIVIGAM, CARIMUNE NF NANOFILTERED, FLEBOGAMMA DIF 10% VIAL, GAMMAGARD LIQUID, GAMMAGARD S-D, GAMMAKED, GAMMAPLEX, GAMUNEX-C, OCTAGAM, PRIVIGEN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
All uses (initial, reauth): Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication). Privigen only: Hyperprolinemia. Octagam only: Allergy to corn. Gammaplex only: Hereditary intolerance to fructose. Infants for whom sucrose or fructose tolerance has not been established.

REQUIRED MEDICAL INFORMATION
Initial: Immune globulin (Ig) will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. For IVIG Ig is being used intravenously (IV) AND One of the following diagnoses: [A] Primary Immunodeficiency 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patients age at the time of diagnosis and the patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine). [B] Secondary Acquired Antibody Deficiency 1) B-cell chronic lymphocytic leukemia with an Ig level less than 500 mg/dL OR history of recurrent bacterial infections. 2) HIV infection with an Ig level less than 400 mg/dL OR Patient has active bleeding or a platelet count less than 10 x 10^9/L. 3) Multiple myeloma in plateau phase and patient has hypogammaglobulinemia. [C] Hematological Autoimmune Disorders 1) Acquired (pure) red cell aplasia (PRCA) that is immunologic and patient had failure, contraindication, or intolerance (F/C/I) to a corticosteroid and an immunosuppressant (i.e., cyclophosphamide, cyclosporine) OR patient has viral PRCA caused by parvovirus B19. 2) Fetal alloimmune thrombocytopenia. 3) Hemolytic disease of the newborn and the patient has established hyperbilirubinemia. 4) Idiopathic thrombocytopenic purpura and patient had F/C/I to a corticosteroid OR a platelet count less than 30,000 cells/mm3. 5) Post-transfusion purpura. Continued in Other Criteria Section.

AGE RESTRICTION
HIV (initial): patient is less than or equal to 12 years of age.
PRESCRIBER RESTRICTION
All uses (initial, reauth): Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g., immunologist, hematologist, neurologist, etc.).

COVERAGE DURATION
4 months: Solid organ transplant. 12 months: all other diagnoses.

OTHER CRITERIA
[D] Neuromuscular Autoimmune Disorders 1) Chronic inflammatory demyelinating polyneuropathy. 2) Guillain-Barr syndrome. 3) Inflammatory myopathies (dermatomyositis and polymyositis) AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, methotrexate, cyclosporine A, cyclophosphamide, or tacrolimus). 4) Lambert-Eaton myasthenic syndrome AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (e.g., azathioprine). 5) Multifocal motor neuropathy. 6) Myasthenia gravis with severe exacerbations or myasthenic crises AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, cyclosporine, cyclophosphamide, or mycophenolate mofetil). 7) Stiff person syndrome AND Patient had F/C/I to at least 2 standard therapies (i.e., benzodiazeapines, muscle relaxants, or anti-convulsants). [E] Other Disorders 1) Autoimmune blistering disease AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., cyclophosphamide, dapsone, methotrexate, azathioprine, or mycophenolate mofetil). 2) Kawasaki syndrome. 3) Solid organ transplant and IVIG is being used for CMV prophylaxis, or patient is a kidney transplant recipient and has donor specific antibodies, or patient has steroid-resistant rejection and had F/C/I to standard therapies. For SCIG (Gamunex-C, Gammagard Liquid, Gammaked only)- Immune globulin is being used subcutaneously AND One of the following PI diagnoses: 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patients age at the time of diagnosis and patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine). All products: Subject to Part B vs. Part D review. For non-oncology renewal, the patient has experienced an objective improvement on immune globulin therapy and the immune globulin will be administered at the minimum effective dose (by decreasing the dose, increasing the frequency, or implementing both strategies) for maintenance therapy.
JAKAFI

MEDICATION(S)
JAKAFI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Myelofibrosis: Diagnosis of primary myelofibrosis, OR post-polycythemia vera myelofibrosis, OR post-essential thrombocythemia myelofibrosis. Polycythemia vera: Diagnosis of polycythemia vera, AND history of failure, contraindication, or intolerance to hydroxyurea.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION
Myelofibrosis, Polycythemia vera: 12 months.

OTHER CRITERIA
Approve for continuation of prior therapy.
JEVTANA

MEDICATION(S)
JEVTANA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prostate Cancer: Diagnosis of castration-resistant metastatic prostate cancer AND patient has been previously treated with a docetaxel-containing regimen AND patient is receiving concurrent prednisone

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
JUXTAPID

MEDICATION(S)
JUXTAPID

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient has been receiving at least 12 consecutive weeks of ONE LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. History of failure after 12 consecutive weeks or intolerance to Repatha therapy. One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: LDL-C greater than or equal to 100 mg/dL with ASCVD OR LDL-C greater than or equal to 130 mg/dL without ASCVD. Not used in combination with Kynamro (mipomersen). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient is not pregnant. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests. Patient is not concomitantly on moderate or strong CYP 3A4 inhibitors (eg, clarithromycin).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.

COVERAGE DURATION
HoFH (initial): 6 months. (reauth): 12 months
OTHER CRITERIA

HoFH (reauthorization): Patient continues to receive statin at the maximally tolerated dose (or other LDL-C lowering prescription therapy if patient is unable to take a statin). Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior Juxtapid therapy) while on Juxtapid therapy. Not used in combination with Kynamro (mipomersen). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient is not pregnant. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests. Patient is not concomitantly on moderate or strong CYP 3A4 inhibitors (eg, clarithromycin).
KADCYLA

MEDICATION(S)
KADCYLA 100 MG VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast cancer: A) Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer AND B) Patient has been previously treated with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of therapy.
KALYDECO

MEDICATION(S)
KALYDECO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cystic Fibrosis (CF) (Initial): Diagnosis of cystic fibrosis. Patient has one of the following mutations on at least one allele in the cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, or S549R. The presence of a mutation was documented by an FDA-cleared cystic fibrosis mutation test and followed by verification with bi-directional sequencing when recommended by the mutation test instructions.

AGE RESTRICTION
CF (Initial): 2 years of age or older

PRESCRIBER RESTRICTION
CF (Initial): Prescribed by or in consultation with a cystic fibrosis specialist.

COVERAGE DURATION
CF (initial, reauth): 12 months

OTHER CRITERIA
CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).
MEDICATION(S)
KANUMA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Lysosomal acid lipase deficiency: Diagnosis of lysosomal acid lipase deficiency (LAL-D). Diagnosis was confirmed by an enzymatic blood (e.g., dried blood spot test) or genetic test.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism, gastroenterologist or lipidologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
KEVEYIS

MEDICATION(S)
KEVEYIS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
All Uses (Initial and Reauth): Hepatic insufficiency (e.g., Child-Pugh class A). Severe pulmonary disease [e.g., severe chronic obstructive pulmonary disease]. Concomitant use with high dose aspirin (i.e., greater than 100 mg per day).

REQUIRED MEDICAL INFORMATION
Periodic paralysis (Initial): Diagnosis of one of the following: Primary hyperkalemic periodic paralysis, Primary hypokalemic periodic paralysis, or Paramyotonia Congenita with periodic paralysis

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses (Initial): Prescribed by or in consultation with a neurologist

COVERAGE DURATION
All uses (Initial): 3 months. (Reauth): 12 months

OTHER CRITERIA
All uses (Reauth): Documentation of positive clinical response to Keveyis therapy.
KEVZARA

MEDICATION(S)
KEVZARA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (initial): Diagnosis of moderately to severely active RA. One of the following: a) Trial and failure, contraindication, or intolerance (TF/C/I) to both Enbrel (etanercept) and Humira (adalimumab) OR b) For continuation of prior Kevzara therapy. (Initial, Reauth): Patient is not receiving Kevzara in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION
Initial, Reauth: 12 months

OTHER CRITERIA
RA (reauth): Documentation of positive clinical response to Kevzara therapy.
KEYTRUDA

MEDICATION(S)
KEYTRUDA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of melanoma and disease is unresectable or metastatic. Non-Small Cell Lung Cancer (NSCLC): Diagnosis of metastatic NSCLC AND tumors express PD-L1 as determined by an FDA-approved test AND patient has history of failure, contraindication, or intolerance to platinum-containing therapy (eg, cisplatin, carboplatin). Head and neck squamous cell carcinoma (HNSCC): Diagnosis of recurrent or metastatic HNSCC AND patient had disease progression on or after platinum-containing chemotherapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
KINERET

MEDICATION(S)
KINERET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Kineret therapy. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) (initial): Diagnosis of NOMID AND dx of NOMID has been confirmed by one of the following: NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation OR evidence of active inflammation including both of the following: clinical symptoms (eg, rash, fever, arthralgia) and elevated acute phase reactants (eg, ESR, CRP). All Uses (initial, reauth): Patient is not receiving Kineret in combination with a biologic disease modifying antirheumatic drug (DMARD) [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Kineret in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA (initial): Prescribed by or in consultation with a rheumatologist. NOMID (initial): Prescribed by or in consultation with allergist/immunologist or rheumatologist or pediatrician.

COVERAGE DURATION
All Uses (initial, reauth): 12 months

OTHER CRITERIA
All Uses (Reauth): Documentation of positive clinical response to Kineret therapy.
KISQALI

MEDICATION(S)
KISQALI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast cancer: Diagnosis of advanced or metastatic breast cancer. Patient is a postmenopausal woman. Cancer is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Kisqali is used in combination with an aromatase inhibitor [(e.g., Femara (letrozole)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
KISQALI-FEMARA PACK

MEDICATION(S)
KISQALI FEMARA CO-PACK

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast cancer: Diagnosis of advanced or metastatic breast cancer. Patient is a postmenopausal woman. Cancer is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
KITABIS PAK

MEDICATION(S)
TOBRAMYCIN PAK 300 MG/5 ML

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of cystic fibrosis (CF) and Pseudomonas Aeruginosa.

AGE RESTRICTION
Patient must be 6 years of age or older.

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Patient must not be pregnant. (CATEGORY D).
KORLYM

MEDICATION(S)
KORLYM

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cushing's syndrome (Initial): Diagnosis of endogenous Cushings syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids). Diagnosis of either type 2 diabetes mellitus or diagnosis of glucose intolerance. Patient has either failed surgery or patient is not a candidate for surgery. Patient is not pregnant.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with an endocrinologist.

COVERAGE DURATION
Initial, reauth: 6 months

OTHER CRITERIA
Reauthorization: Documentation of one of the following: patient has improved glucose tolerance while on Korlym therapy or patient has stable glucose tolerance while on Korlym therapy.
KUVAN

MEDICATION(S)
KUVAN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Phenylketonuria (PKU) (init): Diagnosis of PKU. Patient is a new start to Kuvan (sapropterin dihydrochloride). Patient will have blood Phe levels measured after 1 week of therapy and periodically for up to 2 months of therapy to determine response.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
PKU (Init): 2 months (Reauth): 12 months

OTHER CRITERIA
PKU (reauth): Patient is currently on therapy with Kuvan (sapropterin dihydrochloride). Patient has had an objective response to therapy, defined as a 30% or greater reduction in phenylalanine (Phe) blood levels from baseline. Patient will continue to have blood Phe levels measured periodically during therapy.
KYNAMRO

MEDICATION(S)
KYNAMRO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient has been receiving at least 12 consecutive weeks of ONE LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. History of failure after 12 consecutive weeks or intolerance to Repatha therapy. One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: LDL-C greater than or equal to 100 mg/dL with ASCVD OR LDL-C greater than or equal to 130 mg/dL without ASCVD. Not used in combination with Juxtapid (lomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.

COVERAGE DURATION
HoFH (initial): 6 months. (reauth): 12 months

OTHER CRITERIA

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
HoFH (reauthorization): Patient continues to receive statin at the maximally tolerated dose (or other LDL-C lowering prescription therapy if patient is unable to take a statin). Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior Juxtapid therapy) while on Kynamro therapy. Not used in combination with Juxtapid (lomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests.
KYPROLIS

MEDICATION(S)
KYPROLIS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Myeloma: A) Diagnosis of multiple myeloma AND B) disease is relapsed or refractory AND C) patient has received at least one prior therapy for multiple myeloma.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
LARTRUVO

MEDICATION(S)
LARTRUVO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of soft tissue sarcoma (STS) AND histologic subtype for which an anthracycline-containing regimen is appropriate AND which is not been responsive to curative treatment with radiotherapy or surgery AND being used in combination with doxorubicin.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
LENVIMA

MEDICATION(S)
LENVIMA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Differentiated thyroid cancer (DTC): Diagnosis of DTC. Disease is locally recurrent or metastatic. Patient has symptomatic or progressive disease. Disease is refractory to radioactive iodine treatment.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
LETAIRIS

MEDICATION(S)
LETAIRIS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH (Initial): 6 months. PAH (Reauth): 12 months

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy.
LEUKINE

MEDICATION(S)
LEUKINE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy, AND age greater than or equal to 55 years. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with FN at high risk for infection-associated complications.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
(Initial): Prescribed by hematologist/oncologist except HIVN: Prescribed by

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
hematologist/oncologist or infectious disease specialist

**COVERAGE DURATION**
BMSCT, AML, CFN, FN (prophylaxis), NDDC: 3mo or duration of tx. HIVN: 6mo. FN (treatment): 1 mo.

**OTHER CRITERIA**
HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm^3).
LIDODERM

MEDICATION(S)
LIDOCAINE 5% PATCH

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of post-herpetic neuralgia

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
LONSURF

MEDICATION(S)
LONSURF

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Colorectal Cancer: Diagnosis of metastatic colorectal cancer AND history of failure, contraindication, or intolerance to at least one component in the following: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (e.g., FOLFOX, FOLFIRI, FOLFOXIRI) AND history of failure, contraindication, or intolerance to at least one anti-VEGF therapy (e.g., Avastin) AND One of the following: A) patient has KRAS wild-type tumors and history of failure, contraindication, or intolerance to at least one anti-EGFR therapy (e.g., Vectibix, Erbitux) OR Patient has KRAS mutant tumors.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
LOTRONEX

MEDICATION(S)
ALOSETRON HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) in Women (initial): All of the following: 1) diagnosis of severe diarrhea-predominant IBS, 2) symptoms for at least 6 months, 3) female patient, AND 4) history of failure, contraindication, or intolerance to an antidiarrheal agent [eg, loperamide].

AGE RESTRICTION
Initial: 18 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
IBS (initial): 12 weeks. IBS (reauth): 6 mo.

OTHER CRITERIA
IBS (reauthorization): Symptoms of IBS continue to persist, AND documentation of positive clinical response to Lotronex therapy.
LUMIZYME-MYOZYME

MEDICATION(S)
LUMIZYME, MYOZYME

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pompe disease: Diagnosis of Pompe disease [acid alpha-glucosidase (GAA) deficiency].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
LUPANETA PACK

MEDICATION(S)
LUPANETA PACK

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Endometriosis (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to one NSAID or one oral contraceptive. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Endomet (init, reauth): 6 months

OTHER CRITERIA
Endometriosis (reauthorization): Patient is experiencing recurrence of symptoms after an initial course of therapy.
LUPRON

**MEDICATION(S)**
LEUPROLIDE ACETATE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.

**COVERAGE DURATION**
CPP (initial, reauth), Prostate CA: 12 months

**OTHER CRITERIA**
Prostate Cancer: Approve for continuation of prior therapy. CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.
LUPRON DEPOT

MEDICATION(S)
LUPRON DEPOT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prostate Cancer (7.5 mg, 22.5 mg, 30 mg, 45 mg): Diagnosis of advanced or metastatic prostate cancer. Endometriosis (3.75 mg, 11.25 mg) (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to one NSAID and one oral contraceptive. Uterine Leiomyomata (UL) (3.75 mg, 11.25 mg): a) For use prior to surgery to reduce size of fibroids to facilitate a surgical procedure (eg, myomectomy, hysterectomy) OR b) all of the following: treatment of anemia, anemia is caused by uterine leiomyomata (fibroids), and for use prior to surgery.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Prostate CA: 12 mo. Endomet (init, reauth):6mo. UL (anemia):3 mo (fibroids):4 mo

OTHER CRITERIA
Prostate Cancer (7.5 mg, 22.5 mg, 30 mg, 45 mg): Approve for continuation of prior therapy. Endometriosis (3.75 mg, 11.25 mg) (reauthorization): Patient is experiencing recurrence of symptoms after an initial course of therapy. Used in combination with one of the following: norethindrone 5 mg daily, other "add -back" sex hormones, other bone-sparing agents.
LUPRON DEPOT PED

MEDICATION(S)
LUPRON DEPOT-PED

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.

COVERAGE DURATION
CPP (init,reauth): 12 months

OTHER CRITERIA
CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.
LYNPARZA

MEDICATION(S)
LYNPARZA 50 MG CAPSULE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Ovarian Cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. History of failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
LYNPARZA TABLET

MEDICATION(S)
LYNPARZA 100 MG TABLET, LYNPARZA 150 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Ovarian cancer, advanced disease with known or suspected BRCA mutation with 3 or more prior lines of chemotherapy: Diagnosis of advanced, persistent, or recurrent ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test. History of failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin). Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of one of the following: recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
MARINOL

MEDICATION(S)
DRONABINOL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy. Failure, contraindication, or intolerance to one 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]). Failure, contraindication, or intolerance to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine). AIDS anorexia: Diagnosis of anorexia with weight loss in patients with AIDS. Patient is on antiretroviral therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
CINV: 6 months. AIDS anorexia: 3 months.

OTHER CRITERIA
Subject to Part B vs. Part D review. CINV: Approve for continuation of therapy for treatment covered under Part B when patient is receiving cancer chemotherapy.
MAVYRET

MEDICATION(S)
MAVYRET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Criteria will be applied consistent with current AASLD/IDSA guideline. Submission of medical records (e.g., chart notes, laboratory values) documenting diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6. All patients: Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C), and patient is not receiving Mavyret in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier] OR for continuation of prior Mavyret therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
8 to 16 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
MEKINIST

MEDICATION(S)
MEKINIST

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
MEPRON

MEDICATION(S)
ATOVAQUONE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pneumocystis pneumonia - prophylaxis and acute Pneumocystis pneumonia. Patient with a diagnosis of pneumocystis pneumonia must have a documented allergy or intolerance to Sulfamethoxazole-Trimethoprim. Patient needing prophylaxis for pneumocystis pneumonia must have a documented failure, allergy, or intolerance to one of more of the following, Sulfamethoxazole-Trimethoprim, Dapsone, Aerosolized pentamidine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
MESNEX

MEDICATION(S)
MESNA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Being used for prevention of ifosfamide-induced or cyclophosphamide-induced hemorrhagic cystitis.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
MOZOBIL

MEDICATION(S)
MOZOBIL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Hematopoietic Stem Cell (HSC) Mobilization: Patient with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who will be undergoing autologous HSC transplantation. Used in combination with one granulocyte-colony stimulating factor (G-CSF).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION
One course of therapy up to 4 days

OTHER CRITERIA
N/A
**MS INTERFERONS**

**MEDICATION(S)**
AVONEX, AVONEX PEN, BETASERON, EXTAVIA, PLEGRIDY 125 MCG/0.5 ML SYRING, PLEGRIDY PEN, REBIF, REBIF REBIDOSE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
N/A
MYALEPT

MEDICATION(S)
MYALEPT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Lipodystrophy (initial): Diagnosis of congenital or acquired generalized lipodystrophy AND Patient is refractory to current standards of care for lipid and diabetic management AND One or more of the following metabolic abnormalities are present: A) Insulin resistance (defined as requiring more than 200 units per day), B) Hypertriglyceridemia, or C) Diabetes

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial: Prescribed by or in consultation with an endocrinologist

COVERAGE DURATION
Initial and reauth: 12 months

OTHER CRITERIA
Lipodystrophy (reauth): Patient has experienced an objective response to therapy, such as A) Sustained reduction in hemoglobin A1c (HbA1c) level from baseline OR B) Sustained reduction in triglyceride (TG) levels from baseline
NAGLAZYME

MEDICATION(S)
NAGLAZYME

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Mucopolysaccharidosis (MPS VI): Diagnosis of MPS VI (Maroteaux-Lamy Syndrome)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
MPS VI: 12 months

OTHER CRITERIA
N/A
NATPARA

MEDICATION(S)
NATPARA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Hypocalcemia (Initial): Diagnosis of hypocalcemia due to chronic hypoparathyroidism. NATPARA is not being used in the setting of acute post-surgical hypoparathyroidism. Patient does not have a known calcium-sensing receptor mutation. Patient has a documented parathyroid hormone concentration that is inappropriately low for the level of calcium, recorded on at least two occasions within the previous 12 months. Patient has been optimized on adequate doses of oral calcium (more than 2,000 mg daily) and vitamin D (calcitriol at least 1 microgram/day) supplementation. Patient has normal thyroid-stimulating hormone concentrations if not on thyroid hormone replacement therapy (or if on therapy, the dose had to have been stable for greater than or equal to 3 months). Patient has normal magnesium and serum 25-hydroxyvitamin D concentrations. Creatinine clearance is at least 30 mL/min on two separate measurements, or greater than 60 mL/min (one measurement) with an accompanying serum creatinine concentration of less than 1.5 mg/dL. NATPARA will be used as an adjunct to calcium and vitamin D.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Hypocalcemia (Initial): Prescribed by or in consultation with an endocrinologist.

COVERAGE DURATION
Initial: 4 months. Reauth: 12 months

OTHER CRITERIA
Hypocalcemia (Reauth): One of the following: A) Patient has achieved and maintained serum calcium levels in the ideal range (8 - 9 mg/dL), OR B) Patient has experienced a 50% or greater reduction in oral calcium intake, OR C) Patient has experienced a 50% or greater reduction in oral...
vitamin D intake.
NERLYNX

MEDICATION(S)
NERLYNX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast cancer: Diagnosis of early stage breast cancer. Disease is human epidermal growth factor receptor 2 (HER2)-positive. Patient has received adjuvant Herceptin (trastuzumab)-based therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy if treatment duration of Nerlynx has not exceeded a total of 12 months
NEULASTA

MEDICATION(S)
NEULASTA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Patient was acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses (initial): Prescribed by a hematologist/oncologist

COVERAGE DURATION
FN (treatment), ARS: 1 mo. CFN, NDDC, FN (prophylaxis): 3 mo or duration of tx.

OTHER CRITERIA

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
NEUPOGEN

MEDICATION(S)
NEUPOGEN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Severe chronic neutropenia (SCN): patients with SCN (ie, congenital, cyclic, and idiopathic neutropenias with chronic ANC less than or equal to 500 cells/mm^3). Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with FN at high risk for infection-associated complications.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
Prescribed by hematologist/oncologist except HIVN: Prescribed by hematologist/oncologist or infectious disease specialist

**COVERAGE DURATION**
BMSCT, PBSC, AML, CFN, sec ppx of FN, NDDC: 3 mo or tx duration. SCN, HCN: 12 mo. HIVN: 6 mo. ARS, FN Tx: 1 mo.

**OTHER CRITERIA**
HIV-related neutropenia (HIVN) (off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm^3). Hepatitis C treatment-related neutropenia (HCN) (off-label): One of the following: 1) patients infected with Hepatitis C virus undergoing treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a) who experience neutropenia (ANC less than or equal to 500 cells/mm^3) after dose reduction of Peg-Intron or Pegasys, OR 2) patients who experience interferon-induced neutropenia (ANC less than or equal to 500 cells/mm^3) due to treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a), AND one of the following: a) patient with HIV co-infection, OR b) status post liver transplant, OR c) patient with established cirrhosis.
NEXAVAR

MEDICATION(S)
NEXAVAR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Renal cell carcinoma (RCC): Diagnosis of RCC. One of the following: Relapse following surgical excision OR both medically/surgically unresectable tumor and dx of Stage IV disease.
Hepatocellular carcinoma (HCC): Diagnosis of HCC. One of the following: patient has metastatic disease, or patient has extensive liver tumor burden, or patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only), or both of the following: patient is not a transplant candidate and disease is unresectable.
Differentiated thyroid carcinoma (DTC): Diagnosis of DTC (ie, follicular carcinoma, Hurthle cell carcinoma, or papillary carcinoma). One of the following: locally recurrent disease or metastatic disease. One of the following: patient has symptomatic disease or patient has progressive disease. Disease is refractory to radioactive iodine (RAI) treatment.
Medullary thyroid carcinoma (MTC): Diagnosis of disseminated MTC. Patient has symptomatic disease. History of failure, contraindication, or intolerance to Caprelsa (vandetanib) or Cometriq (cabozantinib).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RCC, DTC, MTC: Prescribed by or in consultation with an oncologist. HCC: Prescribed by or in consultation with an oncologist, hepatologist, or gastroenterologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
NINLARO

MEDICATION(S)
NINLARO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple myeloma: Diagnosis of multiple myeloma. Used in combination with Revlimid (lenalidomide) and dexamethasone. Patient has received at least one prior Velcade (bortezomib)-containing regimen for multiple myeloma.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
NORTHERA

MEDICATION(S)
NORTHERA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Neurogenic orthostatic hypotension (NOH) (init): Diagnosis of symptomatic NOH. NOH is caused by one of the following conditions: primary autonomic failure (eg, Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy. History of failure, contraindication, or intolerance to one of the following agents: fludrocortisone acetate, midodrine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
NOH (init): Prescribed by or in consultation with a cardiologist, neurologist, or nephrologist

COVERAGE DURATION
NOH (init): 1 month (reauth): 12 months

OTHER CRITERIA
NOH (reauth): Documentation of positive clinical response to therapy
NUCALA

MEDICATION(S)
NUCALA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Severe asthma (init): Diagnosis of severe asthma. Asthma is an eosinophilic phenotype as defined by one of the following: baseline peripheral blood eosinophil levels are greater than or equal to 150 cells/microliter or peripheral blood eosinophil levels were greater than or equal to 300 cells/microliter within the past 12 months. Patient has had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12 months or Patient has had any prior intubation for an asthma exacerbation or Patient has had a prior asthma-related hospitalization within the past 12 months. Patient is currently being treated with both a high-dose inhaled corticosteroid (ICS) [eg, fluticasone propionate] and an additional asthma controller medication [eg, leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline] unless intolerance or contraindication to one or all controller medications or one maximally-dosed combination ICS/LABA product [eg, Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)] or intolerance or contraindication to ICS/LABA medications.

AGE RESTRICTION
Severe asthma (init): Age greater than or equal to 12 years

PRESCRIBER RESTRICTION
Severe asthma (init): Prescribed by or in consultation with a pulmonologist or allergy/immunology specialist

COVERAGE DURATION
Severe asthma (init, reauth): 12 months

OTHER CRITERIA
Severe asthma (reauth): Documentation of positive clinical response (eg, reduction in...
exacerbations). Patient is currently being treated with both a high-dose inhaled corticosteroid (ICS) [eg, fluticasone propionate] and an additional asthma controller medication [eg, leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline] unless intolerance or contraindication to one or both medications or one maximally-dosed combination ICS/LABA product [eg, Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)] or intolerance or contraindication to ICS or LABA medications.
NULOJIX

MEDICATION(S)
NULOJIX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Kidney transplant: The medication is being used for prevention of kidney transplant organ rejection AND The patient is immune to the Epstein-Barr virus (i.e. EBV seropositive) AND The patient is prescribed concurrent therapy with mycophenolate and corticosteroids

AGE RESTRICTION
Kidney transplant: 18 years of age or older

PRESCRIBER RESTRICTION
Kidney transplant: Prescriber is experienced in immunosuppressive therapy and management of transplant patients

COVERAGE DURATION
12 months

OTHER CRITERIA
Subject to Part B vs. Part D review. Approve for continuation of prior therapy.
NUPLAZID

MEDICATION(S)
NUPLAZID

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
OCALIVA

MEDICATION(S)
OCALIVA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Primary Biliary Cholangitis (PBC) (initial): Diagnosis of PBC (aka primary biliary cirrhosis). One of the following: a) patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after at least 12 consecutive months of treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol) AND used in combination with UDCA, OR b) history of contraindication or intolerance to UDCA.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PBC (initial): Prescribed by or in consultation with a hepatologist or gastroenterologist.

COVERAGE DURATION
PBC (initial): 6 months, (reauth): 12 months

OTHER CRITERIA
PBC (reauthorization): Submission of medical records (eg, laboratory values) documenting a reduction in ALP level from pre-treatment baseline (ie, prior Ocaliva therapy) while on Ocaliva therapy.
ODOMZO

MEDICATION(S)
ODOMZO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Basal cell carcinoma: Diagnosis of locally advanced basal cell carcinoma AND One of the following: 1) Cancer has recurred following surgery or radiation therapy or 2) Patient is not a candidate for surgery or radiation therapy

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
OFEV

MEDICATION(S)
OFEV

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity) AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Esbriet (pirfenidone).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
IPF (initial): Prescribed by a pulmonologist

COVERAGE DURATION
Initial, reauth: 12 months

OTHER CRITERIA
IPF (reauth): Documentation of positive clinical response to Ofev therapy.
OLYSIO

MEDICATION(S)
OLYSIO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) ONE of the following: 1) Patient has a history of failure, contraindication or intolerance to Harvoni or Zepatier OR 2) For continuation of prior Olysio therapy, AND C) Patient is without decompensated liver disease (defined as Child-Pugh Class B or C)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
12 to 24 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
ONMEL

MEDICATION(S)
ONMEL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
All of the following: 1) Diagnosis of onychomycosis of the toenail as confirmed by one of the following: a) positive potassium hydroxide (KOH) preparation, OR b) culture, OR c) histology, AND 2) patient's condition is causing debility or a disruption in their activities of daily living, AND 3) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
3 months

OTHER CRITERIA
N/A
OPDIVO

MEDICATION(S)
OPDIVO 40 MG/4 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of melanoma and disease is unresectable or metastatic. Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC, disease is metastatic, and history of failure, contraindication, or intolerance to platinum-based chemotherapy (eg, cisplatin, carboplatin). Renal cell carcinoma (RCC): Diagnosis of renal cell carcinoma, and disease is advanced, and history of failure, contraindication, or intolerance to anti-angiogenic therapy (eg, Sutent, Nexavar).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months.

OTHER CRITERIA
Approve for continuation of prior therapy.
OPSUMIT

MEDICATION(S)
OPSUMIT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy.
ORENCIA IV

MEDICATION(S)
ORENCIA 250 MG VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. All indications (Initial, reauth): One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Oencia IV therapy. Patient is not receiving Oencia in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Oencia in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA, JIA (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION
All indications (Initial, reauth): 12 months

OTHER CRITERIA
All indications (Reauth): Documentation of positive clinical response to Oencia therapy.
ORENCIA SC

MEDICATION(S)
ORENCIA 125 MG/ML SYRINGE, ORENCIA 50 MG/0.4 ML SYRINGE, ORENCIA 87.5 MG/0.7 ML SYRINGE, ORENCIA CLICKJECT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Orecia SC therapy, OR prior maintenance therapy of at least 4 weeks with Orecia IV. Patient is not receiving Orecia in combination with a biologic disease modifying antirheumatic drug (DMARD) [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Orecia in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION
All indications: (Initial, reauth): 12 months

OTHER CRITERIA
RA (Reauth): Documentation of positive clinical response to Orecia therapy. Patient is not receiving Orecia in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Orecia in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].
ORENITRAM

MEDICATION(S)
ORENITRAM ER

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy.
ORFADIN

MEDICATION(S)
ORFADIN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of: hereditary tyrosinemia type 1. The patient has had a slit-lamp examination of his/her eyes prior to the initiation of therapy with Orfadin.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
ORKAMBI

MEDICATION(S)
ORKAMBI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cystic Fibrosis (CF) (Initial): Diagnosis of CF. Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene. The presence of the mutation was documented by an FDA-cleared cystic fibrosis mutation test or Clinical Laboratory Improvement Amendments-approved facility.

AGE RESTRICTION
CF (Initial): Patient is 6 years of age or older

PRESCRIBER RESTRICTION
CF (Initial): Prescribed by or in consultation with a specialist affiliated with a CF care center

COVERAGE DURATION
CF (initial, reauth): 12 months

OTHER CRITERIA
CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations)
OTEZLA

MEDICATION(S)
OTEZLA 28 DAY STARTER PACK, OTEZLA 30 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Psoriatic arthritis (PsA, initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. PsA, plaque psoriasis (initial): History of failure, contraindication, or intolerance to both Humira and Enbrel, OR for continuation of prior Otezla therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PsA (init): Prescribed by or in consultation with a dermatologist or rheumatologist. Plaque psoriasis (init): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION
Initial, Reauth: 12 months

OTHER CRITERIA
Reauthorization (all indications): Documentation of positive clinical response to Otezla therapy.
**OXANDRIN**

**MEDICATION(S)**
OXANDROLONE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Promote weight gain (initial): Medication will be used as an adjunct therapy to promote weight gain AND One of the following: Extensive surgery, Chronic infections, Severe trauma, Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons AND History of failure, contraindication, or intolerance to nutritional supplements AND a nutritional consult was performed. Counterbalance protein catabolism (initial): Oxandrin will be used to counterbalance protein catabolism associated with chronic corticosteroid administration. Bone pain (initial): Diagnosis of bone pain associated with osteoporosis.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
bone pain (initial, reauth): 1 month. Others (initial, reauth): 3 months

**OTHER CRITERIA**
All diagnoses (reauth): patient has experienced an objective improvement (i.e. weight gain, increase in lean body mass, or reduction in muscle pain/weakness)
<table>
<thead>
<tr>
<th>MEDICATION(S)</th>
<th></th>
</tr>
</thead>
</table>
| A-HYDROCORT, ABELCET, ACETYLCYSTEINE 10% VIAL, ACETYLCYSTEINE 20% VIAL, ACTIMMUNE, ACYCLOVIR 1,000 MG/20 ML VIAL, ACYCLOVIR 500 MG/10 ML VIAL, ADRUCIL, ALBUTEROL 2.5 MG/0.5 ML SOL, ALBUTEROL 5 MG/Ml SOLUTION, ALBUTEROL SUL 0.63 MG/3 ML SOL, ALBUTEROL SUL 1.25 MG/3 ML SOL, ALBUTEROL SUL 2.5 MG/3 ML SOLN, AMBISOME, AMIFOSTINE, AMINO ACIDS 15% SOLUTION, AMINOSYN II, AMINOSYN II WITH ELECTROLYTES, AMINOSYN WITH ELECTROLYTES, AMINOSYN-HBC, AMINOSYN-PF, AMINOSYN-RF, AMPHOTERICIN B, AMPICILLIN 1 GM ADD-VANTAGE VL, AMPICILLIN 1 GM VIAL, AMPICILLIN 10 GM VIAL, AMPICILLIN 125 MG VIAL, AMPICILLIN-SULBACTAM, ANZEMET, APREPITANT, ARGATROBAN, ARGATROBAN-0.9% NACL, ARRANON, ASTAGRAF XL, ATGAM, AZATHIOPRINE, AZATHIOPRINE SODIUM, AZITHROMYCIN I.V. 500 MG VIAL, BACIIM, BETHKIS, BICNU, BLEOMYCIN SULFATE 30 UNIT VIAL, BROVANA, BUDESONIDE 0.25 MG/2 ML SUSP, BUDESONIDE 0.5 MG/2 ML SUSP, BUDESONIDE 1 MG/2 ML INH SUSP, BUSULFAN, BUSULFEX, BUTORPHANOL 1 MG/ML VIAL, BUTORPHANOL 2 MG/ML VIAL, CALCITRIOL 0.25 MCG CAPSULE, CALCITRIOL 0.5 MCG CAPSULE, CALCITRIOL 1 MCG/ML AMPUL, CALCITRIOL 1 MCG/ML SOLUTION, CANDIDAS, CAPASTAT SULFATE, CARBOPLATIN, CASPOFUNGIN ACETATE, CEFAZOLIN SODIUM, CEFEPIME HCL, CEFFOXITIN, CEFTRIAXONE 1 GM PIGGYBACK, CEFTRIAXONE 1 GM-D5W BAG, CEFTRIAXONE 2 GM ADD VIAL, CEFTRIAXONE 2 GM PIGGYBACK, CEFTRIAXONE 2 GM VIAL, CEFTRIAXONE 2 GM-D5W BAG, CEFTRIAXONE 250 MG VIAL, CEFTRIAXONE 500 MG VIAL, CEFUROXIME SODIUM, CELLEXPT 200 MG/ML ORAL SUSP, CELLCEPT 500 MG VIAL, CEREBYX 500 MG PE/10 ML VIAL, CHLORAMPHENICOL SOD SUCCINATE, CHLOROTHIAZIDE SODIUM, CISPLATIN, CLADRIBINE, CLINIMIX, CLINIMIX E, CLOFARABINE, CLOYAR, COLISTIMETHATE, COSMEGEN, CROMOLYN 20 MG/2 ML NEB SOLN, CUBICIN, CYCLOPHOSPHAMIDE 25 MG CAPSULE, CYCLOPHOSPHAMIDE 50 MG CAPSULE, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYTARABINE, DACARBazine 200 MG VIAL, DAPTOMYCIN, DAUNORUBICIN HCL, DAUNOXOME, DECITABINE, DESMOPRESSIN 40 MCG/10 ML VIAL, DESMOPRESSIN AC 4 MCG/ML AMPUL, DESMOPRESSIN AC 4 MCG/ML VIAL, DEXTROSE 10%-0.2% NACL, DEXTROSE 10%-0.45% NACL, DEXTROSE 2.5%-0.45% NACL, DEXTROSE 5%-0.2% NACL, DEXTROSE 5%-0.2% NACL-KCL, DEXTROSE 5%-0.225% NACL, DEXTROSE 5%-0.225% NACL-KCL, DEXTROSE 5%-0.3% NACL, DEXTROSE 5%-0.3% NACL-KCL, DEXTROSE 5%-0.33% NACL, DEXTROSE 5%-0.33% NACL-KCL, DEXTROSE 5%-0.45% NACL, DEXTROSE 5%-0.45% NACL-KCL, DEXTROSE 5%-0.9% NACL, DEXTROSE 5%-1/2NS-KCL, DEXTROSE 5%-NS-KCL, KCL 20 MEQ IN D5W SOLUTION, KCL 40 MEQ IN D5W SOLUTION, DEXTROSE IN LACTATED RINGERS, DEXTROSE 10%-WATER IV SOLUTION, DEXTROSE 5%-WATER 100 ML, DEXTROSE 5%-WATER 50 ML, DEXTROSE 5%-WATER IV SOLUTION 242 ML
VIAL, DILTIAZEM 125 MG/25 ML VIAL, DILTIAZEM 25 MG/5 ML VIAL, DILTIAZEM 50 MG/10 ML VIAL, DILTIAZEM HCL 100 MG VIAL, DIPHENHYDRAMINE 50 MG/ML VIAL, DOCEFREZ 20 MG VIAL, DOCETAXEL 140 MG/7 ML VIAL, DOCETAXEL 160 MG/16 ML VIAL, DOCETAXEL 160 MG/8 ML VIAL, DOCETAXEL 20 MG/2 ML VIAL, DOCETAXEL 20 MG/ML VIAL, DOCETAXEL 200 MG/20 ML VIAL, DOCETAXEL 80 MG/4 ML VIAL, DOCETAXEL 80 MG/8 ML VIAL, DOXERCALCIFEROL, DOXIL, DOXORUBICIN HCL, DURAMORPH, ELITEK 1.5 MG VIAL, ELLENCE, EMEND 125 MG CAPSULE, EMEND 125 MG POWDER PACKET, EMEND 40 MG CAPSULE, EMEND 80 MG CAPSULE, EMEND TRIPACK, ENGERIX-B 20 MCG/ML SYRN, ENGERIX-B PEDIATRIC-adolescent, ENVARSUS XR, ERWINAZE, ERYTHROCYTIN 500 MG ADDVNT VL, ERYTHROCYTIN 500 MG VIAL, ESOMEPEAZOLE SODIUM, ETOPOPHOS, ETOPOSIDE 1,000 MG/50 ML VIAL, ETOPOSIDE 100 MG/5 ML VIAL, ETOPOSIDE 500 MG/25 ML VIAL, FAMOTIDINE 20 MG PIGGYBACK, FAMOTIDINE 20 MG/2 ML VIAL, FAMOTIDINE 200 MG/20 ML VIAL, FAMOTIDINE 40 MG/4 ML VIAL, FAMOTIDINE 500 MG/50 ML VIAL, FASLODEX, FLUCONAZOLE IN DEXTROSE, FLUCONAZOLE-NS 200 MG/100 ML, FLUCONAZOLE-NS 400 MG/200 ML, FLUCONAZOLE-NACL 200 MG/100 ML, FLUCONAZOLE-NACL 400 MG/200 ML, FLUDARABINE PHOSPHATE, FLUOROURACIL 1,000 MG/20 ML VL, FLUOROURACIL 2,500 MG/50 ML VL, FLUOROURACIL 2.5 GM/50 ML BTL, FLUOROURACIL 2.5 GM/50 ML VIAL, FLUOROURACIL 5 GM/100 ML VIAL, FLUOROURACIL 5,000 MG/100 ML, FLUOROURACIL 500 MG/10 ML VIAL, FOSPHENYTOIN 100 MG PE/2 ML VL, FREAMINE HBC, Furosemide 100 MG/10 ML SYRINGE, Furosemide 100 MG/10 ML VIAL, Furosemide 20 MG/2 ML VIAL, Furosemide 40 MG/4 ML SYRINGE, Furosemide 40 MG/4 ML VIAL, FUSILEV, GABLOFEN 10,000 MCG/20 ML VIAL, GABLOFEN 40,000 MCG/20 ML VIAL, GABLOFEN 50 MCG/ML SYRINGE, GANCICLOVIR SODIUM, GEMCITABINE HCL 1 GRAM VIAL, GENGRAF, GENTAMICIN 10 MG/ML VIAL, GENTAMICIN 20 MG/2 ML VIAL, GENTAMICIN 40 MG/ML VIAL, GENTAMICIN 80 MG/2 ML VIAL, GENTAMICIN 800 MG/20 ML VIAL, GENTAMICIN PED 20 MG/2 ML VIAL, GLUCOSE IN WATER, GRANISETRON HCL 1 MG TABLET, HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE 100, HEPARIN 10,000 UNIT/10 ML VIAL, HEPARIN 30,000 UNIT/30 ML VIAL, HEPARIN 40,000 UNITS/4 ML VIAL, HEPARIN 50,000 UNIT/10 ML VIAL, HEPARIN 50,000 UNITS/10 ML VL, HEPARIN 50,000 UNITS/5 ML VIAL, HEPARIN SOD 1,000 UNIT/ML VIAL, HEPARIN SOD 10,000 UNIT/ML VL, HEPARIN SOD 20,000 UNIT/ML VL, HEPARIN SOD 5,000 UNIT/ML VIAL, HEPARIN 20,000 UNIT/500 ML-D5W, HEPARIN-D5W 25,000 UNIT/250 ML, HEPARIN-D5W 25,000 UNIT/500 ML, HEPATAMINE, HYDRALAZINE 20 MG/ML VIAL, HYDROMORPHONE 10 MG/ML VIAL, HYDROMORPHONE 50 MG/5 ML VIAL, HYDROMORPHONE 500 MG/50 ML VIAL, HYDROMORPHONE HCL 10 MG/ML AMP, HYDROMORPHONE HCL 10 MG/ML VL, IDAMYCIN PFS, IDARUBICIN HCL, IFOSFAMIDE, IMOVAX RABIES VACCINE, INTRALIPID, IPRATROPIUM BR 0.02% SOLN, IPRATROPIUM-ALBUTEROL, IRINOCITAN HCL 100 MG/5
ML VL, LACTATED RINGERS INJECTION, LEUCOVORIN CALCIUM 100 MG VIAL, LEUCOVORIN CALCIUM 200 MG VIAL, LEUCOVORIN CALCIUM 350 MG VIAL, LEUCOVORIN CALCIUM 50 MG VIAL, LEUCOVORIN CALCIUM 500 MG VL, LEVALBUTEROL CONCENTRATE, LEVALBUTEROL HCL, LEVOCARNITINE 1 G/10 ML SOLN, LEVOCARNITINE 330 MG TABLET, LEVOLEUCOVORIN 175 MG/17.5 ML, LEVOLEUCOVORIN 250 MG/25 ML VL, LEVOLEUCOVORIN 50 MG VIAL, LIDOCAINE HCL 0.5% VIAL, LIDOCAINE HCL 1% 20 MG/2 ML, LIDOCAINE HCL 1% 20 MG/2 ML VL, LIDOCAINE HCL 1% 300 MG/30 ML, LIDOCAINE HCL 1% 50 MG/5 ML, LIDOCAINE HCL 1% 50 MG/5 ML VL, LIDOCAINE HCL 1% AMPUL, LIDOCAINE HCL 1% VIAL, LIDOCAINE HCL 2% 100 MG/5 ML, LIDOCAINE HCL 2% 40 MG/2 ML, LIDOCAINE HCL 2% 40 MG/2 ML VL, LIDOCAINE HCL 2% AMPUL, LIDOCAINE HCL 2% VIAL, LIORESAL INTRATHECAL, MAGNESIUM SULFATE 50% SYRINGE, MAGNESIUM SULFATE 50% VIAL, MELPHALAN HCL, METHADONE HCL 10 MG/ML VIAL, METHADONE HCL 200 MG/20 ML VL, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, METOCLOPRAMIDE 10 MG/2 ML VIAL, METOPROLOL 1 MG/ML CARPUJECT, METOPROLOL TART 5 MG/5 ML AMP, METOPROLOL TART 5 MG/5 ML VIAL, MITOMYCIN, MITOXANTRONE HCL, MORPHINE 10 MG/ML ISECURE SYRG, MORPHINE 2 MG/ML ISECURE SYR, MORPHINE 4 MG/ML ISECURE SYR, MORPHINE 8 MG/ML ISECURE SYRG, MUSTARGEN, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, Nafcillin 1 GM ADD-VAN VIAL, Nafcillin 1 GM VIAL, Nafcillin 10 GM BULK VIAL, Nafcillin 10 GM VIAL, Nalbuphine HCL, Nebupent, Neoral, Nephiramine, Nipent, Nitroglycerin 5 MG/ML VIAL, Nutrilipid, Olanzapine 10 MG VIAL, Ondansetron 4 MG/5 ML Solution, Ondansetron HCL 24 MG TABLET, Ondansetron HCL 4 MG TABLET, Ondansetron HCL 8 MG TABLET, Ondansetron ODT, Oxaliplatin 100 MG/20 ML VIAL, Paclitaxel, Pamidronate 30 MG/10 ML VIAL, Pamidronate 60 MG/10 ML VIAL, Pamidronate 90 MG/10 ML VIAL, Paricalcitol 1 MCG Capsule, Paricalcitol 2 MCG Capsule, Paricalcitol 4 MCG Capsule, Penicillin G Potassium, Penicillin G Sodium, Perforomist, Phenytoin 100 MG/2 ML VIAL, Phenytoin 250 MG/5 ML VIAL, Phenytoin 50 MG/ML AMPUL, Phenytoin 50 MG/ML VIAL, Potassium Chl-Normal Saline, Potassium Cl 10 MEQ/100 ML SOL, Potassium Cl 10 MEQ/5 ML Conc, Potassium Cl 10 MEQ/50 ML SOL, Potassium Cl 2 MEQ/ML VIAL, Potassium Cl 20 MEQ/10 ML Conc, Potassium Cl 20 MEQ/100 ML SOL, Potassium Cl 20 MEQ/50 ML SOL, Potassium Cl 40 MEQ/100 ML SOL, Potassium Cl 40 MEQ/20 ML Conc, Potassium Chloride In D5LR, Potassium Chloride-Nacl, Premasol, Procainamide 1,000 MG/10 ML VL, Procainamide 100 MG/ML VIAL, Procalamine, Prograf 5 MG/ML Ampule, Propranolol 1 MG/ML VIAL, Prosol, Pulmozyme, Rabavert, Ranitidine HCL 150 MG/6 ML VL, Ranitidine HCL 50 MG/2 ML VIAL, Rapamune 1 MG Tablet, Rapamune 1 MG/ML Oral Soln, Rapamune 2 MG Tablet,
DETAILS
This drug may be covered under Medicare Part B or D depending on the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.
PEG-INTRON

MEDICATION(S)
PEGINTRON, PEGINTRON REDIPEN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION

OTHER CRITERIA
HepC (reauth): patient has an undetectable HCV RNA at week 24, additional treatment weeks of peginterferon are required to complete treatment regimen, and patient has not exceeded 48 wks of therapy with peginterferon.
PEGASYS

MEDICATION(S)
PEGASYS, PEGASYS PROCLICK

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION

OTHER CRITERIA
N/A
PENTAM

MEDICATION(S)
PENTAM 300

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pneumocystis carinii pneumonia. HIV infection - Pneumocystis pneumonia, Prophylaxis. Monitoring of the following is necessary prior to and during treatment: CBC, platelet counts, serum calcium concentrations, hepatic function, and ECG. Daily BUN, serum creatinine, and blood glucose levels.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
PERJETA

MEDICATION(S)
PERJETA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Metastatic breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. One of the following: a) patient has not received prior anti-HER2 therapy or chemotherapy for metastatic disease AND used in combination with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel), OR b) patient was previously treated with chemotherapy and Herceptin (trastuzumab) without Perjeta AND used in combination with Herceptin (trastuzumab). Non-metastatic breast cancer: One of the following diagnoses: HER2-positive early stage breast cancer, HER2-positive locally advanced breast cancer, or HER2-positive inflammatory breast cancer. Used in combination with both Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Uses: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
PHENOXYBENZAMINE

MEDICATION(S)
PHENOXYBENZAMINE HCL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Used in the treatment of pheochromocytoma, to control episodes of hypertension and sweating.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months.

OTHER CRITERIA
N/A
POMALYST

MEDICATION(S)
POMALYST

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone. Patient has received two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor [eg, Velcade (bortezomib) or Kyprolis (carfilzomib)] or has a contraindication or intolerance to Revlimid and proteasome inhibitors. Patient has experienced disease progression on or within 60 days of completion of last therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
PRALUENT

MEDICATION(S)
PRALUENT PEN, PRALUENT SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Initial: Submission of medical records (eg, chart notes, laboratory values) documenting one of the following diagnoses: Heterozygous familial hypercholesterolemia (HeFH) as confirmed by one of the following: (1) Documented assessment of patient using Dutch Lipid Clinic Network diagnostic criteria with a cumulative score greater than or equal to 9 points (ie, definite FH), or (2) Presence of tendinous xanthomas in patient, first degree relative, or second degree relative, AND Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult, or (3) Genetic confirmation of a mutation in the LDL receptor, ApoB, or PCSK9. OR Atherosclerotic cardiovascular disease (ASCVD) as confirmed by acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. One of the following LDL-C values while on maximally tolerated statin therapy within the last 30 days or if statin intolerant and on other maximally tolerated lipid-lowering regimen: (1) LDL-C greater than or equal to 100 mg/dL with ASCVD, or (2) LDL-C greater than or equal to 130 mg/dL without ASCVD. Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior to Praluent therapy) while on Praluent therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial, reauth: Prescribed by a cardiologist, endocrinologist, or lipid specialist

COVERAGE DURATION

OTHER CRITERIA
EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
HeFH/ASCVD (initial): One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one high-intensity statin and will continue to receive a HIGH-INTENSITY statin [ie, atorvastatin 40-80 mg, Crestor (rosuvastatin) 20-40 mg] at maximally tolerated dose, OR (2) Both of the following: A) Patient is unable to tolerate a high-intensity statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), AND B) One of the following: a. Patient has been receiving at least 12 consecutive weeks of one moderate-intensity or low-intensity statin and will continue to receive a MODERATE-INTENSITY or LOW-INTENSITY statin [ie, atorvastatin 10-20 mg, Crestor (rosuvastatin) 5-10 mg, simvastatin 10-40 mg, pravastatin 10-80 mg, lovastatin 20-40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1-4 mg] at maximally tolerated dose, OR b. Patient is unable to tolerate a moderate-intensity or low-intensity statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), OR (3) Patient has a labeled contraindication to a statin as documented in medical records, or (4) Patient has experienced rhabdomyolysis on one statin. HeFH/ASCVD (reauth): Patient continues to receive a statin at the maximally tolerated dose (unless patient has documented inability to take a statin). (Initial, reauth): Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
PROMACTA

MEDICATION(S)
PROMACTA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic immune (idiopathic) thrombocytopenic purpura (ITP) (initial): Diagnosis of relapsed/refractory chronic ITP for greater than 6 months. Baseline platelet count is less than 50,000/mcL. Patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding. One of the following: A) History of failure, intolerance, contraindication to corticosteroids or immune globulin OR B) History of failure or contraindication to splenectomy. Chronic hepatitis C (initial): Diagnosis of chronic hepatitis C. Patient has thrombocytopenia defined as platelets less than 90,000/mcL for initiation (pre-treatment) of interferon therapy. Severe aplastic anemia (initial): Diagnosis of severe aplastic anemia. Patient has a platelet count less than 30,000/mcL. History of failure, intolerance, or contraindication to immunosuppressive therapy with antithymocyte globulin and cyclosporine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Chronic ITP and SAA: Prescribed by or in consultation with a hematologist/oncologist. Chronic hepatitis C associated thrombocytopenia: Prescribed by or in consultation with a hematologist/oncologist, gastroenterologist, hepatologist, or infectious disease specialist.

COVERAGE DURATION

OTHER CRITERIA
ITP (reauth): After at least 4 weeks of therapy at the maximum weekly dose (10 mcg/kg), the platelet count increased to a sufficient level to avoid clinically important bleeding. Hepatitis C (reauth): Platelets less than 75,000/mcL for maintenance of optimal interferon-based therapy.
Aplastic anemia (reauth): Patient has experienced an increase in platelet count.
PROVIGIL

MEDICATION(S)
MODAFINIL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Obstructive sleep apnea/hypopnea syndrome (OSAHS) (Initial): Diagnosis (dx) of OSAHS defined by one of the following: 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), or both of the following: 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), and 1 of the following symptoms: unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, or breathing interruptions during sleep. Shift-work sleep disorder (SWSD) (Initial): Dx of SWSD confirmed by symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, or sleep study demonstrating loss of a normal sleep-wake pattern (ie, disturbed chronobiologic rhythmicity). No other medical condition or medication accounts for the symptoms. Narcolepsy (initial): Dx of narcolepsy as confirmed by sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). MS Fatigue (initial): Dx of multiple sclerosis (MS). Patient is experiencing fatigue. Depression (initial): Treatment-resistant depression defined as diagnosis of major depressive disorder (MDD) or bipolar depression, AND history of failure, contraindication, or intolerance to at least two antidepressants from different classes (eg, SSRIs, SNRIs, bupropion). Used as adjunctive therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
OSAHS/MS/dep(init), SWSD (init,reauth): 3 mo. OSAHS/dep(reauth): 12 mo. MS (reauth): 6 mo. Other: 12 mo

OTHER CRITERIA
QUALAQUIN

MEDICATION(S)
QUININE SULFATE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Malaria: Diagnosis of uncomplicated malaria. One of the following: 1) Treatment in areas of chloroquine-sensitive malaria, and failure, contraindication, or intolerance to chloroquine or hydroxychloroquine, OR 2) Treatment in areas of chloroquine-resistant malaria. Not used for the treatment or prevention of nocturnal leg cramps.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
7 days

OTHER CRITERIA
N/A
REGRANEX

MEDICATION(S)
REGRANEX

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diabetic Neuropathic Ulcers: Patient has a lower extremity diabetic neuropathic ulcer. Treatment will be given in combination with ulcer wound care (eg, debridement, infection control, and/or pressure relief).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
5 months

OTHER CRITERIA
N/A
MEDICATION(S)
RELISTOR 150 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Opioid-induced Constipation: Diagnosis of opioid induced constipation in adult patients with chronic non-cancer pain.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
6 months

OTHER CRITERIA
Documentation of opioid use for at least 4 weeks prior to the start of therapy AND history of failure, contraindication or intolerance to Amitiza.
**MEDICATION(S)**
REMICADE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (Initial): Diagnosis (Dx) of moderately to severely active CD or FCD. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall). Ulcerative colitis (UC) (Initial): Dx of moderately to severely active UC. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)]. Rheumatoid arthritis (RA) (Initial): Dx of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), OR failure, contraindication, or intolerance to methotrexate (Rheumatrex/Trexall). Ankylosing spondylitis (AS) (Initial): Dx of active AS. Failure, contraindication, or intolerance to two NSAIDs. Psoriatic arthritis (PsA) (Initial): Dx of active PsA. Plaque psoriasis (Initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. Sarcoidosis (initial): Failure, contraindication, or intolerance to one immunosuppressant [eg, methotrexate (Rheumatrex/Trexall), cyclophosphamide, or azathioprine (Imuran)] AND failure, contraindication, or intolerance to one corticosteroid (eg, prednisone). All indications (Initial, reauth): Patient is not receiving Remicade in combination with a biologic DMARD [eg, Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra)]. Patient is not receiving Remicade in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
CD, FCD, UC (Initial): Prescribed by or in consultation with a gastroenterologist. RA, AS (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a dermatologist. All indications (Initial, reauth): Prescribed by or in consultation with a rheumatologist.
consultation with rheumatologist or dermatologist. Plaque Psoriasis (Initial): Prescribed by or in consultation with a dermatologist. Sarcoidosis (Initial): Prescribed by or in consultation with a pulmonologist, dermatologist, ophthalmologist.

COVERAGE DURATION
All indications (initial, reauth): 12 months

OTHER CRITERIA
All indications (Reauth): Documentation of positive clinical response to Remicade therapy.
REMODULIN

MEDICATION(S)
REMODULIN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy.
REPATHA

MEDICATION(S)
REPATHA PUSHTRONEX, REPATHA SURECLICK, REPATHA SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
HeFH/ASCVD (initial): Submission of medical records (eg, chart notes, laboratory values) documenting one of the following diagnoses: Heterozygous familial hypercholesterolemia (HeFH) as confirmed by one of the following: (1) Documented assessment of patient using Dutch Lipid Clinic Network diagnostic criteria with a cumulative score greater than or equal to 9 points (ie, definite FH), or (2) Presence of tendinous xanthomas in patient, first degree relative, or second degree relative, AND Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult, or (3) Genetic confirmation of a mutation in the LDL receptor, ApoB, or PCSK9. OR Atherosclerotic cardiovascular disease (ASCVD) as confirmed by acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. HoFH (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of homozygous familial hypercholesterolemia as confirmed by one of the following: (1) Genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or (2) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, AND either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents. HeFH/ASCVD/HoFH (initial): One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: (1) LDL-C greater than or equal to 100 mg/dL with ASCVD, or (2) LDL-C greater than or equal to 130 mg/dL without ASCVD.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HeFH/ASCVD/HoFH (init, reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
**COVERAGE DURATION**


**OTHER CRITERIA**

HeFH/ASCVD (initial): One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one maximally-tolerated statin therapy and will continue to receive a statin at maximally tolerated dose, or (2) Patient is unable to tolerate statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), or (3) Submission of medical records documenting patient has a labeled contraindication to all statins, or (4) Patient has experienced rhabdomyolysis on one statin therapy. HoFH (initial): One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one maximally-tolerated statin therapy and will continue to receive a statin at maximally tolerated dose, or (2) both of the following: a) One of the following: 1. Patient is unable to tolerate statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), or 2. Submission of medical records documenting patient has a labeled contraindication to all statins, or 3. Patient has experienced rhabdomyolysis on one statin therapy, AND b) patient has been receiving at least 12 consecutive weeks of other LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. HeFH/ASCVD (reauth): Patient continues to receive statin at the maximally tolerated dose (unless patient has documented inability to take statins). HoFH (reauth): Patient continues to receive statin at the maximally tolerated dose (or other LDL-C lowering prescription therapy if patient is unable to take a statin). HeFH/ASCVD/HoFH (reauth): Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior to Repatha therapy) while on Repatha therapy. HeFH/ASCVD/HoFH (Initial, reauth): Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. HoFH (Initial, reauth): Not used in combination with Juxtapid (lomitapide) or Kynamro (mipomersen).
REVATIO

**MEDICATION(S)**
REVATIO 10 MG/ML ORAL SUSP, SILDENAFIL, SILDENAFIL CITRATE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. For Revatio injection only (Initial): Patient is temporarily unable to take oral medications. For Revatio oral suspension only (initial, reauth): One of the following: A) History of intolerance to generic Revatio tablets, OR B) Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following: age, oral-motor difficulties, or dysphagia.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

**COVERAGE DURATION**
PAH: Initial - 6 months. Reauth - 12 months.

**OTHER CRITERIA**
PAH (Reauth): Documentation of positive clinical response to therapy
REVLIMID

MEDICATION(S)
REVLIMID

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple myeloma (MM): Diagnosis of MM. Myelodysplastic syndromes (MDS): Patient has transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle cell lymphoma (MCL): Diagnosis of MCL. Disease has relapsed or progressed after two prior therapies (eg, bortezomib, bendamustine, cladribine, rituximab).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
Rheumatoid Arthritis (RA) (init): Patient is not receiving Rituxan in combination with a biologic DMARD [eg, Enbrel (etanercept), Ocrecia (abatacept), Kineret (anakinra)]. Patient is not receiving Rituxan in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

REQUIRED MEDICAL INFORMATION
Non-Hodgkin’s Lymphoma (NHL): As first-line treatment of diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based chemotherapy regimens, or as first-line treatment of follicular, CD20-positive, B-cell NHL in combination with chemotherapy, or as a single-agent maintenance therapy for the treatment of follicular, CD20-positive, B-cell NHL in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, or for the treatment of low-grade, CD20-positive, B-cell NHL in patients with stable disease following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy or who achieve a partial or complete response following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy, or diagnosis of relapsed or refractory, low grade or follicular CD20-positive, B-cell non-Hodgkin’s lymphoma. Rheumatoid Arthritis (RA) (init): Concurrently on or contraindication, or intolerance to methotrexate. Failure, contraindication, or intolerance (F/C/I) to a TNF antagonist (eg, adalimumab, etanercept, infliximab). Wegener’s Granulomatosis (WG) and Microscopic Polyangiitis (MPA): Patient is concurrently on glucocorticoids (eg, prednisone) OR contraindication or intolerance to glucocorticoids (eg, prednisone). Immune or idiopathic thrombocytopenic purpura (ITP): F/C/I to one of the following: corticosteroids, immunoglobulins, or splenectomy. Documented platelet count of less than 50x10^9 /L.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
ITP: Prescribed by or in consultation with a hematologist or oncologist. RA: Prescribed by or in...
consultation with a rheumatologist. WG, MPA: Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.

**COVERAGE DURATION**
All uses except RA, WG, MPA: 12 mos. RA: 3 months. WG, MPA: 3 months only.

**OTHER CRITERIA**
Approve for continuation of prior therapy.
RUBRACA

MEDICATION(S)
RUBRACA 200 MG TABLET, RUBRACA 300 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Ovarian cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious BRCA mutation as detected by an FDA-approved diagnostic test (e.g., FoundationFocus CDxBRCA Assay). History of failure, contraindication, or intolerance to two or more chemotherapies (e.g., cisplatin, carboplatin).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
RUCONEST

MEDICATION(S)
RUCONEST

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Berinert, Firazyr, or Kalbitor).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
RYDAPT

**MEDICATION(S)**
RYDAPT

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
All indications: Prescribed by or in consultation with a hematologist or oncologist.

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Approve for continuation of prior therapy
SABRIL

MEDICATION(S)
SABRIL, VIGABATRIN

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Complex Partial Seizures (CPS): For use as adjunctive therapy. Failure, contraindication, or intolerance to two formulary anticonvulsants [eg, Lamictal (lamotrigine), Depakene (valproic acid), Dilantin (phenytoin)]. Infantile Spasms (IS): Diagnosis of infantile spasms.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
SANDOSTATIN

MEDICATION(S)
OCTREOTIDE 1,000 MCG/5 ML VIAL, OCTREOTIDE 1,000 MCG/ML VIAL, OCTREOTIDE 5,000 MCG/5 ML VIAL, OCTREOTIDE ACET 0.05 MG/ML VL, OCTREOTIDE ACET 100 MCG/ML AMP, OCTREOTIDE ACET 100 MCG/ML VL, OCTREOTIDE ACET 200 MCG/ML VL, OCTREOTIDE ACET 50 MCG/ML AMP, OCTREOTIDE ACET 50 MCG/ML VIAL, OCTREOTIDE ACET 500 MCG/ML AMP, OCTREOTIDE ACET 500 MCG/ML VL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) patient is not a candidate for surgical resection or pituitary irradiation AND History of failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All Uses (Initial and reauth): 12 months

OTHER CRITERIA
Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): patient has improvement in number of diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (reauth): patient has improvement in number of diarrhea episodes.
MEDICATION(S)
SANDOSTATIN LAR, SANDOSTATIN LAR DEPOT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) patient is not a candidate for surgical resection or pituitary irradiation AND History of failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea and flushing episodes AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Vasoactive peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All Uses (Initial and reauth): 12 months

OTHER CRITERIA
Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): patient has improvement in number of diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (reauth): patient has improvement in number of diarrhea episodes.
SEROSTIM

MEDICATION(S)
SEROSTIM

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
HIV wasting (Initial): Diagnosis of HIV-associated wasting syndrome or cachexia, and one of the following: unintentional weight loss greater than 10% over the last 12 months, or unintentional weight loss greater than 7.5% over the last 6 months, or loss of 5% body cell mass (BCM) within 6 months, or body mass index (BMI) less than 20 kg/m2, or patient is male and has BCM less than 35% of total body weight (TBW) and BMI less than 27 kg/m2, or patient is female and has BCM less than 23% of TBW and BMI less than 27 kg/m2. Nutritional evaluation since onset of wasting first occurred. Anti-retroviral tx has been optimized to decrease the viral load. Patient has not had weight loss as a result of other underlying treatable conditions (eg, depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes). Patient has tried and had an inadequate response or intolerance to dronabinol or megestrol acetate.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Initial, Reauth: Prescribed by or in consultation with an infectious disease specialist.

COVERAGE DURATION
Initial: 3 months, Reauth: 6 months

OTHER CRITERIA
HIV wasting (reauth): Evidence of positive response to therapy. One of the following targets or goals has not been achieved: weight, BCM, BMI. Patient is currently receiving treatment with antiretrovirals.
MEDICATION(S)
SIGNIFOR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cushing's disease (initial): Diagnosis of Cushings disease AND History of failure or patient is not a candidate for pituitary surgery.

AGE RESTRICTION
Initial: 18 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Initial: 3 months. Reauth: 12 months.

OTHER CRITERIA
Cushing's disease (reauth): a clinically meaningful reduction in 24-hour urinary free cortisol levels or improvement in signs or symptoms of the disease.
SIGNIFOR LAR

MEDICATION(S)
SIGNIFOR LAR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acromegaly (initial): Diagnosis of acromegaly AND History of failure to surgery or patient is not a candidate for surgery

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Initial: 6 months. Reauthorization: 12 months.

OTHER CRITERIA
Acromegaly (reauth): patients growth hormone (GH) level or insulin-like growth factor 1 (IGF-1) level for age and gender has normalized/improved
SILIQ

MEDICATION(S)
SILIQ

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. One of the following: A) Failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab) AND trial, failure, contraindication, or intolerance to Cosentyx (secukinumab), OR B) for continuation of prior Siliq therapy. Patient is not receiving Siliq in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Plaque Psoriasis (Initial): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION
All indications (Initial, reauth): 12 months

OTHER CRITERIA
All indications (Reauth): Documentation of positive clinical response to Siliq therapy. Patient is not receiving Siliq in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].
SOLARAZE

MEDICATION(S)
DICLOFENAC SODIUM 3% GEL, SOLARAZE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
The patient has a diagnosis of actinic keratoses.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
6 months

OTHER CRITERIA
Lesions that do not respond to treatment should be carefully reevaluated and management reconsidered.
SOMATULINE DEPOT

MEDICATION(S)
SOMATULINE DEPOT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to one of the following: surgery or radiotherapy, OR B) not a candidate for one of the following: surgery or radiotherapy. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (initial): Diagnosis of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All Indications (Initial and reauth): 12 months

OTHER CRITERIA
Acromegaly (reauth): patient had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). GEP-NETs (reauth): Approve for continuation of therapy.
SOMAVERE

MEDICATION(S)
SOMAVERSE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acromegaly (initial): Diagnosis of acromegaly AND History of failure to surgery and/or radiation therapy and/or other medical therapies (such as dopamine agonists [e.g., bromocriptine, cabergoline]) unless patient is not a candidate for these treatment options AND History of failure or intolerance to generic octreotide (a somatostatin analogue)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Initial and reauth: 12 months

OTHER CRITERIA
Acromegaly (reauth): Patient has experienced an objective response to therapy (biochemical control, decrease or normalization of IGF-1 levels).
SOVALDI

**MEDICATION(S)**
SOVALDI

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Criteria will be applied consistent with current AASLD/IDSA guideline. For genotype 1 patients and Sovaldi used in combination with Olysio: Patient is without decompensated liver disease (defined as Child-Pugh Class B or C). For genotype 3 patients without decompensated cirrhosis (defined as Child-Pugh Class B or C), using Sovaldi in combination with ribavirin: Patient is peginterferon ineligible*. For genotype 3 patients with cirrhosis, using Sovaldi in combination with Daklinza: Patient is peginterferon ineligible*. All genotype 1 (except Sovaldi plus Olysio therapy): history of intolerance or contraindication to Harvoni OR Zepatier therapy OR patient is currently on Sovaldi therapy. All Sovaldi plus Olysio therapy: history of failure, intolerance or contraindication to Harvoni OR Zepatier therapy OR patient is currently on Sovaldi therapy. All Sovaldi plus Daklinza therapy: One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) therapy, OR 2) patient has failed prior therapy with an NS5A-containing regimen AND submission of medical records (eg, chart notes) documenting that the patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

**COVERAGE DURATION**
12 to 48 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

**OTHER CRITERIA**

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
*Peginterferon ineligibility confirmed by medical record documentation (eg, chart note, lab values) of one of the following: intolerance to interferon, autoimmune hepatitis or other autoimmune disorders, hypersensitivity to peginterferon or any of its components, major uncontrolled depressive illness, baseline neutrophil count below 1500/uL, baseline platelet count below 90,000/uL, baseline hemoglobin below 10 g/dL, decompensated hepatic disease or history of preexisting cardiac disease.
SPORANOX

MEDICATION(S)
ITRACONAZOLE, SPORANOX 10 MG/ML SOLUTION

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
One of the following: 1) patient has a systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis), OR 2) patient is resistant to topical antifungal treatment and has one of the following diagnoses: a) tinea corporis (ringworm), OR b) tinea cruris (jock itch), OR c) tinea pedis (athletes foot), OR d) tinea capitis (scalp ringworm), OR e) pityriasis versicolor, OR 3) all of the following: a) patient has a diagnosis of onychomycosis confirmed by one of the following (CAPSULE ONLY): i) positive potassium hydroxide (KOH) preparation, OR ii) culture, OR iii) histology, AND b) the patients condition is causing debility or a disruption in their activities of daily living, AND c) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine, OR 4) patient has a diagnosis of candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole (ORAL SOLUTION ONLY).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
systemic fungal infxn:6mo. (candidiasis, fingernail onycho.):1 mo. (toenail onycho, other):3mo.

OTHER CRITERIA
N/A
SPRYCEL

MEDICATION(S)
SPRYCEL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML): One of the following: A) Diagnosis of newly diagnosed Ph+ CML in the chronic phase AND Patient is positive for Ph+ or BCR-ABL positive as detected by bone marrow cytogenetics, FISH or PCR OR B) Diagnosis of Ph+ CML AND History of failure, resistance, or relapse to prior tyrosine kinase inhibitor therapy with GLEEVEC [imatinib] or TASIGNA AND Patient has received mutation testing AND Patient does not have the T315I mutation OR C) Diagnosis of Ph+ CML with intolerance to prior tyrosine kinase inhibitor therapy with GLEEVEC [imatinib] or TASIGNA. Ph+ acute lymphoblastic leukemia (ALL): Diagnosis of Ph+ ALL.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION
All Uses: 12 months

OTHER CRITERIA
All Uses: Approve for continuation of prior therapy.
STELARA

MEDICATION(S)
STELARA 45 MG/0.5 ML SYRINGE, STELARA 90 MG/ML SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Plaque psoriasis (Initial - 45mg/0.5mL): Diagnosis of moderate to severe plaque psoriasis. Plaque psoriasis (Initial - 90mg/1mL): Diagnosis of moderate to severe plaque psoriasis. Patient’s weight is greater than 100 kg (220 lbs). Psoriatic arthritis (PsA) (Initial - 45mg/0.5mL): Diagnosis of active PsA. PsA (Initial - 90mg/1mL): Diagnosis of active PsA. Patient’s weight is greater than 100 kg (220 lbs). Diagnosis of co-existent moderate to severe psoriasis. Plaque psoriasis (Initial): One of the following: a) History of failure, contraindication, or intolerance (F/C/I) to Enbrel (etanercept) OR Humira (adalimumab) OR b) for continuation of prior Stelara therapy. PsA (Initial): One of the following: a) History of failure, contraindication, or intolerance (F/C/I) to Enbrel (etanercept) and Humira (adalimumab) OR b) for continuation of prior Stelara therapy. Crohn's disease (CD) (Initial): Diagnosis of moderately to severely active Crohn’s disease. One of the following: a) History of F/C/I to Humira (adalimumab) OR b) History of F/C/I to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)], OR c) for continuation of prior Stelara therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. CD (initial): Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION
All uses (Initial, reauth): 12 months

EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
OTHER CRITERIA
Reauthorization (all indications): Documentation of positive clinical response to Stelara therapy. All indications (initial, reauth): Patient is not receiving Stelara in combination with either of the following: Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)] or a Janus Kinase Inhibitor [eg, Xeljanz (toficitinib)].
STELARA IV

MEDICATION(S)
STELARA 130 MG/26 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of moderately to severely active Crohn's disease. One of the following: a) History of failure, contraindication, or intolerance to Humira (adalimumab), or (b) History of failure, contraindication, or intolerance to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)]. Patient is not receiving Stelara in combination with either of the following: Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)] or a Janus Kinase Inhibitor [eg, Xeljanz (tofacitinib)]. Patient is not receiving Stelara in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION
One time

OTHER CRITERIA
Stelara is to be administered as an intravenous induction dose. Stelara induction dosing is in accordance with the United States Food and Drug Administration approved labeled dosing for Crohn's Disease: 260 mg for patients weighing 55 kg or less, 390 mg for patients weighing more than 55 kg to 85 kg, or 520 mg for patients weighing more than 85 kg.
STIVARGA

MEDICATION(S)
STIVARGA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Metastatic colorectal cancer (mCRC): All of the following: 1) diagnosis of mCRC, AND 2) history of failure, contraindication or intolerance to fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, AND 3) history of failure, contraindication or intolerance to an anti-VEGF therapy (e.g. Avastin [bevacizumab]), AND 4) one of the following: a) KRAS mutation, OR b) both of the following: KRAS wild-type and history of failure, contraindication or intolerance to an anti-EGFR therapy [e.g. Vectibix (panitumumab), Erbitux (cetuximab)]. Gastrointestinal stromal tumor (GIST): All of the following: 1) diagnosis of locally advanced, unresectable or metastatic GIST, AND 2) history of failure, contraindication or intolerance to both of the following: a) Gleevec (imatinib mesylate), AND b) Sutent (sunitinib malate).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
STRENSIQ

**MEDICATION(S)**
STRENSIQ

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Hypophosphatasia: Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia AND for patients requesting the 80 mg/0.8 mL vial only: Patient's weight is greater than or equal to 40 kg

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Hypophosphatasia: Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism or endocrinologist.

**COVERAGE DURATION**
Hypophosphatasia: 12 months

**OTHER CRITERIA**
N/A
SUTENT

MEDICATION(S)
SUTENT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma. Gastrointestinal stromal tumor (GIST): Diagnosis of GIST after disease progression on or intolerance to Gleevec (imatinib). Pancreatic neuroendocrine tumors: Diagnosis of progressive, well-differentiated pancreatic neuroendocrine tumor that is unresectable, locally advanced, or metastatic disease.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
All Indications: 12 months

OTHER CRITERIA
All Indications: Approve for continuation of prior therapy
SYLATRON

MEDICATION(S)
SYLATRON

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of melanoma with microscopic or gross nodal involvement AND the prescribed medication will be used as adjuvant therapy within 84 days of definitive surgical resection, including complete lymphadenectomy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
SYLVANT

MEDICATION(S)
SYLVANT 100 MG VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multicentric Castleman's disease (MCD) (Initial): Diagnosis of MCD. Patient is human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
MCD (Initial): Prescribed by or in consultation with hematologist/oncologist or rheumatologist.

COVERAGE DURATION
MCD (initial, reauth): 6 months

OTHER CRITERIA
MCD (reauth): Documentation of positive clinical response to Sylvant therapy. Patient is HIV negative and HHV-8 negative.
SYNAGIS

MEDICATION(S)
SYNAGIS 50 MG/0.5 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Patient will use palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) during the peak months of infection in the patients geographic region AND Patient meets one of the following criteria: 1) Infants born at 28 weeks, six days gestation or earlier and who are younger than 12 months of age at the start of the RSV season OR 2) Diagnosis of chronic lung disease of prematurity, born before 32 weeks, 0 days gestation, received greater than 21% oxygen for at least the first 28 days after birth, and one of the following: a) 12 months of age or younger at the start of the RSV season OR b) greater than 12 months of age to 24 months of age at the start of the RSV season and received medical support (i.e., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) within 6 months before the start of the second RSV season. OR 3) Patient is 12 months of age or younger at the start of the RSV season and has one of the following: a) a cyanotic heart failure that will require a cardiac surgical procedure and the patient is receiving medication to control congestive heart failure, OR b) moderate to severe pulmonary hypertension OR c) cyanotic heart defect. OR 4) patient is younger than 24 months of age and will or has undergone a cardiac transplantation during the RSV season. OR 5) Patient is 12 months of age or younger at the start of the RSV season with a congenital abnormality or neuromuscular disorder and has an impaired ability to clear secretions from the upper airway due to an ineffective cough. OR 6) Patient is younger than 24 months of age with a lymphocyte count below the normal range for patients age and has received or will receive a solid organ transplant, hematopoietic stem cell transplant recipient, or chemotherapy during the RSV season.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a pediatric specialist (i.e., pulmonologist, neonatologist, neurologist, cardiologist, pediatric intensivist, or infectious disease specialist)
COVERAGE DURATION
12 months

OTHER CRITERIA
Approve 5 doses based on patient body weight for all other indications.
SYNRIBO

MEDICATION(S)
SYNRIBO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic myelogenous leukemia (CML): Diagnosis of CML in the chronic or accelerated phase AND Patient has tried and has had resistance, relapse, inadequate response, intolerance or is contraindicated to TWO tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL, TASIGNA, BOSULIF, ICLUSIG)

AGE RESTRICTION
CML: 18 years of age or older

PRESCRIBER RESTRICTION
CML: Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TAFINLAR

MEDICATION(S)
TAFINLAR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TAGRISSO

MEDICATION(S)
TAGRISSO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC. Tumors are positive for epidermal growth factor receptor (EGFR) T790M mutation. The patient has experienced disease progression on or after one of the following EGFR Tyrosine Kinase Inhibitors (TKIs): Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TALTZ

MEDICATION(S)
TALTZ AUTOINJECTOR (3 PACK), TALTZ SYRINGE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Taltz therapy. Patient is not receiving Taltz in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Taltz in combination with a Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]. Patient is not receiving Taltz in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Plaque psoriasis (Initial): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION
All indications (Initial, reauth): 12 months

OTHER CRITERIA
All indications (Reauth): Documentation of positive clinical response to Taltz therapy. Patient is not receiving Taltz in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Taltz in combination with a Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]. Patient is not receiving Taltz in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].
TARCEVA

MEDICATION(S)
TARCEVA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of locally advanced or metastatic (Stage III or IV) NSCLC AND One of the following: A) Failure of at least one prior chemotherapy regimen AND TARCEVA will be used as monotherapy OR B) No evidence of disease progression after four cycles of first-line platinum-based chemotherapy (i.e. TARCEVA used as maintenance treatment) AND TARCEVA will be used as monotherapy OR C) Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 (L858R) substitution mutation as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility.
Pancreatic Cancer: Diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer AND TARCEVA will be used in combination with gemcitabine.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
All Indications: 12 months

OTHER CRITERIA
All Indications: Approve for continuation of prior therapy.
TARGRETIN

MEDICATION(S)
BEXAROTENE, TARGRETIN 1% GEL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cutaneous T-Cell Lymphoma (CTCL): Diagnosis of CTCL. History of failure, contraindication, or intolerance to at least one prior therapy (including skin-directed therapies [eg, corticosteroids {ie, clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate}] or systemic therapies [eg, interferons]).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TASIGNA

MEDICATION(S)
TASIGNA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic myelogenous leukemia (CML): One of the following: A) Diagnosis of newly diagnosed Philadelphia chromosome positive (Ph+) CML in the chronic phase AND Patient is positive for Ph+ or BCR-ABL positive as detected by bone marrow cytogenetics, FISH or PCR OR B) Diagnosis of Ph+ CML AND History of failure, resistance, or relapse to prior tyrosine kinase inhibitor therapy with GLEEVEC [imatinib] or SPRYCEL AND Patient has received mutation testing AND Patient does not have the T315I mutation OR C) Diagnosis of Ph+ CML with intolerance to prior tyrosine kinase inhibitor therapy with GLEEVEC [imatinib] or SPRYCEL

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TAZORAC

MEDICATION(S)
TAZAROTENE, TAZORAC

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Acne vulgaris (initial): Diagnosis of acne vulgaris AND History of failure or intolerance to at least two topical acne products (e.g., tretinoin, adapalene, benzoyl peroxide, clindamycin, erythromycin, or azelaic acid). Plaque psoriasis (initial): Diagnosis of stable moderate to severe plaque psoriasis AND Patient has body surface area (BSA) involvement of less than 20 percent AND History of failure or intolerance to at least two topical psoriasis products (e.g., medium to high potency corticosteroids and/or vitamin D analogs).

AGE RESTRICTION
Acne (initial): 12 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
All uses (Initial and reauth): 12 months

OTHER CRITERIA
Acne, Plaque psoriasis (reauth): Documentation of positive clinical response to therapy.
TECENTRIQ

**MEDICATION(S)**
TECENTRIQ

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Urothelial carcinoma: Diagnosis of locally advanced or metastatic urothelial carcinoma. One of the following: A) History of disease progression during or following platinum-containing chemotherapy, OR B) History of disease progression within 12 months of neoadjuvant or adjuvant chemotherapy, OR C) Patient is not eligible for cisplatin-containing chemotherapy. Non-small cell lung cancer: All of the following: A) Diagnosis of metastatic non-small cell carcinoma (NSCLC), and B) Patient has disease progression following platinum-containing chemotherapy, and C) One of the following: 1) Patient does not have epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement OR 2) Both of the following: patient has an EGFR mutation AND history of failure, contraindication, or intolerance to at least one anti-EGFR therapy (e.g., Gilotrif [afatinib], Iressa [gefitinib], Tarceva [erlotinib]) OR 3) Both of the following: patient has ALK rearrangement AND history of failure, contraindication, or intolerance to at least one ALK inhibitor (e.g., Xalkori [crizotinib])

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with an oncologist.

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Approve for continuation of prior therapy.
TECFIDERA

MEDICATION(S)
TECFIDERA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
TECHNIVIE

MEDICATION(S)
TECHNIVIE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline, AND B) Patient is not receiving Technivie in combination with another HCV direct acting antiviral agent [eg, Harvoni (ledipasvir-sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir)], AND C) ONE of the following: History of intolerance or contraindication to Harvoni or Zepatier therapy OR patient is currently on Technivie therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
12 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
TESTOSTERONE

MEDICATION(S)
ANDRODERM, ANDROGEL 1%(5G) GEL PACKET, ANDROGEL 1.62% GEL PUMP,
ANDROGEL 1.62%(1.25G) GEL PCKT, ANDROGEL 1.62%(2.5G) GEL PCKT, TESTOSTERONE
10 MG GEL PUMP, TESTOSTERONE 12.5 MG/1.25 GRAM, TESTOSTERONE 25 MG/2.5 GM
PKT, TESTOSTERONE 50 MG/5 GRAM GEL, TESTOSTERONE 50 MG/5 GRAM PKT,
TESTOSTERONE CYPIONATE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient. 1) Two pre-treatment serum
total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has
a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder,
HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or
bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3)
History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg,
congenital anorchia, Klinefelter’s syndrome).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION

OTHER CRITERIA
HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2)
Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted,
OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver
disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within
or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.
TESTOSTERONE ENANTHATE

MEDICATION(S)
TESTOSTERONE ENANTHATE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient. 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP in males. Breast cancer (BC): Dx for the palliative treatment of inoperable BC in women.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION

OTHER CRITERIA
HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2) Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.
THALOMID

MEDICATION(S)
THALOMID

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone, unless the patient has an intolerance to steroids. Erythema nodosum leprosum (ENL): Diagnosis of moderate to severe ENL with cutaneous manifestations. Thalomid is not used as monotherapy if moderate to severe neuritis is present.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
MM: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TOBI (TOBRAMYCIN)

MEDICATION(S)
TOBI PODHALER, TOBRAMYCIN 300 MG/5 ML AMPULE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Diagnosis of cystic fibrosis (CF) and Pseudomonas Aeruginosa.

AGE RESTRICTION
Patient must be 6 years of age or older.

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Patient must not be pregnant. (CATEGORY D).
TOPICAL RETINOIDS

MEDICATION(S)
AVITA, TRETINOIN 0.01% GEL, TRETINOIN 0.025% CREAM, TRETINOIN 0.025% GEL, TRETINOIN 0.05% CREAM, TRETINOIN 0.1% CREAM, TRETINOIN MICROSPHERE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION

AGE RESTRICTION
PA applies to members 26 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
N/A
TRACLEER

MEDICATION(S)
TRACLEER 125 MG TABLET, TRACLEER 62.5 MG TABLET

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH AND PAH is symptomatic AND
One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B)
Patient is currently on any therapy for the diagnosis of PAH

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist

COVERAGE DURATION
PAH (Initial): 6 months. PAH (Reauth): 12 months

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to therapy
TRELSTAR

MEDICATION(S)
TRELSTAR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TYGACIL

MEDICATION(S)
TIGECYCLINE, TYGACIL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Indicated for treatment of: Complicated skin and skin structure infections, Complicated intra-abdominal infections, or Community-acquired bacterial pneumonia. Reserve for use in any indication when alternatives are not suitable. If the patient has severe hepatic impairment (Child Pugh C), an initial dose of 100 mg of Tygacil should be given followed by a maintenance dose of 25 mg every 12 hours.

AGE RESTRICTION
The patient must be at least 18 years old

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
30 days

OTHER CRITERIA
Not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia.
TYKERB

MEDICATION(S)
TYKERB

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Breast Cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer. Used in combination with one of the following: Herceptin (trastuzumab) or aromatase inhibitors [eg, Aromasin (exemestane), Femara (letrozole), Arimidex (anastrazole)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
TYMLOS

**MEDICATION(S)**
TYMLOS

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Initial: Patient is a postmenopausal woman. Either of the following: set I) diagnosis of osteoporosis defined as bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND one of the following: a) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis or distal forearm or b) trial and failure, contraindication, or intolerance to one osteoporosis treatment (e.g., alendronate, risendronate, zoledronic acid, Prolia (denosumab)), or set II) diagnosis of osteopenia defined as BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) and one of the following: a) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis or distal forearm, or b) both of the following: history of failure, contraindication, or intolerance to one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]) and one of the following FRAX (Fracture Risk Assessment Tool) 10-year probabilities: major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or hip fracture is 3% or more in the U.S., or the country-specific threshold in other countries or regions. Trial and failure, contraindication, or intolerance to Forteo (teriparatide). Treatment duration with Tymlos and if taken in the past, Forteo (teriparatide), has not exceeded a total of 24 months during the patient's lifetime.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
Initial, reauth: 12 months
OTHER CRITERIA

Reauth: Documentation of a positive clinical response to Tymlos (abaloparatide) therapy. Treatment duration with Tymlos and if taken in the past, Forteo (teriparatide), has not exceeded a total of 24 months during the patient's lifetime.
TYSABRI

MEDICATION(S)
TYSABRI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses). Failure, contraindication, or intolerance (F/C/I) to one of the following: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone or Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Rebif (interferon beta-1a), or Tecfidera (dimethyl fumarate). Patient is not taking Tysabri in combination with another MS agent [eg, Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Lemtrada (alemtuzumab), Rebif (interferon beta-1a), or Tecfidera (dimethyl fumarate)]. Crohn's Disease (CD) (initial): Diagnosis of moderate to severe CD with evidence of inflammation (eg, elevated C-reactive protein [CRP], elevated erythrocyte sedimentation rate, presence of fecal leukocytes). History of inadequate response or intolerance to one of the following conventional therapies: corticosteroids, 6-mercaptopurine (6MP [Purinethol], azathioprine (Imuran), methotrexate, aminosalicylates (eg, sulfasalazine, mesalamine, olsalazine). History of inadequate response or intolerance to a TNF-inhibitor (eg, Cimzia [certolizumab pegol], Humira [adalimumab], Remicade [infliximab]). CD (initial and reauth): Patient is not taking Tysabri in combination with an immunosuppressant (eg, 6-MP, azathioprine, cyclosporine, or methotrexate) or a TNF-inhibitor (eg, Enbrel [etanercept], Humira [adalimumab], or Remicade [infliximab]).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
EFFECTIVE DATE 10/24/2017
LAST UPDATED 11/2017
MS: 12mo. CD (Init): 3 mo. CD (Reauth): 6 mo if not on steroids. Otherwise, 3 mo.

OTHER CRITERIA
CD (reauth): Diagnostic and/or clinical documentation (eg, improved disease activity index) that indicates patient has experienced clinical benefit from receiving (induction) Tysabri therapy by week 12.
TYZEKA

MEDICATION(S)
TYZEKA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Documented diagnosis of chronic hepatitis B (HBeAg positive or negative) with evidence of viral replication and either evidence of persistent elevations in liver enzymes or histological disease and compensated liver disease. For HBeAg pos: HBV DNA less than $9 \log_{10}$ copies per mL and ALT greater than or equal to $2 \times$ upper limit of normal (ULN) prior to treatment. For HBeAg neg: HBV DNA less than $7 \log_{10}$ copies per mL prior to treatment.

AGE RESTRICTION
16 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
6 months

OTHER CRITERIA
N/A
UPTRAVI

MEDICATION(S)
UPTRAVI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (initial): Diagnosis of PAH AND Patient is symptomatic AND One of the following: a) Diagnosis of PAH was confirmed by right heart catheterization OR b) patient is currently on any therapy for the diagnosis of PAH. One of the following: a) History of inadequate response, contraindication, or intolerance to a PDE5 inhibitor (ie, Adcirca, Revatio) or Adempas (riociguat), and History of inadequate response, contraindication, or intolerance to an endothelin receptor antagonist [e.g. Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)] OR b) For continuation of prior Uptravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue (eg, epoprostenol, iloprost, treprostinil).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist

COVERAGE DURATION
Initial: 6 months Reauth: 12 months

OTHER CRITERIA
PAH (Reauth): Documentation of positive clinical response to Uptravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue (eg, epoprostenol, iloprost, treprostinil)
VALCHLOR

MEDICATION(S)
VALCHLOR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) (initial): All of the following: 1) diagnosis of Stage IA MF-CTCL, OR diagnosis of Stage IB MF-CTCL, AND 2) patient has received at least one prior skin-directed therapy [e.g., topical corticosteroids, bexarotene topical gel (Targretin topical gel), topical nitrogen mustard, etc.].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
**VECTIBIX**

**MEDICATION(S)**
VECTIBIX 100 MG/5 ML VIAL

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Colorectal Cancer: Diagnosis of metastatic colorectal cancer. One of the following: (1) Relapsed, refractory, or disease progression on one chemotherapy regimen containing fluoropyrimidine [eg, Xeloda (capecitabine), 5-FU/Adrucil (fluorouracil)] or Eloxatin (oxaliplatin) or Camptosar (irinotecan), or (2) use in combination with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan), or (3) intolerance to intensive therapy (eg, FOLFOX, FOLFIRI), or (4) used as monotherapy in patients not appropriate for intensive therapy. Tumor expresses wild-type KRAS gene and wild type NRAS gene.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with an oncologist

**COVERAGE DURATION**
Colorectal Cancer: 6 months

**OTHER CRITERIA**
Approve for continuation of prior therapy.
VELCADE

MEDICATION(S)
VELCADE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Multiple myeloma (MM): Diagnosis of MM. Mantle cell lymphoma (MCL): Diagnosis of MCL.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
MM, MCL: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
**VENCLEXTA**

**MEDICATION(S)**
VENCLEXTA, VENCLEXTA STARTING PACK

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL): Diagnosis of CLL or SLL with 17p deletion or TP53 mutation. Patient has received at least one prior therapy for CLL/SLL [e.g., Cytoxan (cyclophosphamide), Fludara (fludarabine), Rituxan (rituximab)].

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Prescribed by or in consultation with a hematologist or oncologist

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
Approve for continuation of prior therapy.
VENTAVIS

MEDICATION(S)
VENTAVIS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION
PAH (Initial): 6 months. (Reauth): 12 months

OTHER CRITERIA
Subject to Part B vs D review. PAH (Reauth): Documentation of positive clinical response to therapy.
**VFEND**

**MEDICATION(S)**
VORICONAZOLE

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Invasive Aspergillosis, Candidemia (nonneutropenic), Candidiasis of the esophagus, Disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds. Serious infections due to Scedosporium apiospermum and Fusarium species in patients intolerant of, or refractory to other therapies.

**AGE RESTRICTION**
Patient must be at least 12 years old.

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
6 months

**OTHER CRITERIA**
Serum transaminase levels (AST and ALT) prior to start of VFEND therapy.
MEDICATION(S)
VIBERZI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Irritable bowel syndrome with diarrhea (IBS-D) (initial): Diagnosis of IBS-D. History of failure, contraindication, or intolerance to an antidiarrheal agent [eg, loperamide].

AGE RESTRICTION
IBS-D (initial): 18 years of age or older

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
IBS-D (initial): 12 weeks. IBS-D (reauth): 12 mo.

OTHER CRITERIA
IBS-D (reauth): Documentation of positive clinical response to Viberzi therapy
VIVITROL

MEDICATION(S)
VIVITROL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Alcohol dependence, opioid dependence (init, reauth): 24 weeks

OTHER CRITERIA
Alcohol dependence, opioid dependence (reauth): Confirmation of clinical benefit to the patient.
VOSEVI

MEDICATION(S)
VOSEVI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Criteria will be applied consistent with current AASLD/IDSA guideline. Submission of medical records (e.g., chart notes, laboratory values) documenting diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6. All patients: Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C), and patient is not receiving Vosevi in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier]. All genotype 1 and 4: trial and failure, intolerance, or contraindication to Harvoni and Zepatier therapy OR for continuation of prior Vosevi therapy. All genotype 2 and 3: trial and failure, intolerance, or contraindication to Epclusa OR for continuation of prior Vosevi therapy. All genotype 5 and 6: trial and failure, intolerance, or contraindication to Epclusa and Harvoni therapy OR for continuation of prior Vosevi therapy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
12 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
VOTRIENT

MEDICATION(S)
VOTRIENT

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Renal cell carcinoma (RCC): Diagnosis of advanced/metastatic RCC. Soft tissue sarcoma: Diagnosis of advanced soft tissue sarcoma and patient received at least one prior chemotherapy (e.g., ifosfamide, doxorubicin, cisplatin, dacarbazine, docetaxel, oxaliplatin, etc.)

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All Uses: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
VPRIV

MEDICATION(S)
VPRIV

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Gaucher disease: Diagnosis of type 1 Gaucher disease. Patient has evidence of symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Gaucher disease: 12 months

OTHER CRITERIA
N/A
**XADAGO**

**MEDICATION(S)**
XADAGO

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Parkinsons disease (PD) (Initial): Diagnosis of PD. ALL of the following: A) Patient is experiencing “off” episodes AND B) patient has tried and failed any product containing Levodopa/Carbidopa generic or brand (e.g. Sinemet, Sinemet CR, Rytary, Stalevo) AND C) patient will continue to use levodopa/carbidopa in combination with Xadago.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
Initial and Reauth: 12 months

**OTHER CRITERIA**
PD (Reauth): Documentation of positive clinical response to therapy.
XALKORI

MEDICATION(S)
XALKORI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of locally advanced or metastatic (stage IIIB or IV) NSCLC AND One of the following: A) Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility or B) Patient has MET amplification- or ROS1 rearrangements-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
NSCLC: Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
XELJANZ

MEDICATION(S)
XELJANZ, XELJANZ XR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria), OR for continuation of prior tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
RA (Initial): Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION
RA (initial, reauth): 12 months

OTHER CRITERIA
RA (Reauth): Documentation of positive clinical response to tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).
XENAZINE

MEDICATION(S)
TETRABENAZINE

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION

AGE RESTRICTION
Tardive dyskinesia (Initial): Age greater than or equal to 18 years.

PRESCRIBER RESTRICTION
HD (Initial): Prescribed by or in consultation with a neurologist. Tardive dyskinesia, Tourette’s syndrome (Initial): Prescribed by or in consultation with neurologist or psychiatrist.

COVERAGE DURATION
All indications: (Initial) 3 months, (Reauth) 12 months.

OTHER CRITERIA
All indications (Reauth): Documentation of clinical response and benefit from therapy.
**XERMELO**

**MEDICATION(S)**
XERMELO

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Carcinoid syndrome diarrhea (Initial): Diagnosis of carcinoid syndrome diarrhea AND diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months AND used in combination with SSA therapy.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
Initial: Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist

**COVERAGE DURATION**
Initial: 6 months, Reauth: 12 months

**OTHER CRITERIA**
Carcinoid syndrome diarrhea (Reauthorization): Documentation of a positive clinical response to Xermelo therapy AND Xermelo will continue to be used in combination with SSA therapy.
XGEVA

MEDICATION(S)
XGEVA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Bone metastasis from solid tumors (BMST) (initial): Both of the following: 1) diagnosis of solid tumors (eg, breast cancer, kidney cancer, lung cancer, prostate cancer, thyroid cancer), AND 2) documented evidence of one or more metastatic bone lesions. Giant cell tumor of bone (GCTB): Both of the following: 1) diagnosis of giant cell tumor of bone AND 2) One of the following: a) tumor is unresectable, OR b) surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy (HCM) (initial): Both of the following: 1) diagnosis of hypercalcemia of malignancy, AND 2) history of failure, contraindication, or intolerance to one intravenous bisphosphonate (eg, Aredia (pamidronate), Zometa (zoledronic acid)).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
GCTB, HCM (initial): Prescribed by or in consultation with an oncologist

COVERAGE DURATION
BMST, GCTB: 12 mo. HCM (initial, reauth): 2 mo.

OTHER CRITERIA
GCTB (reauth): Approve for continuation of therapy. HCM (reauth): Documentation of positive clinical response to Xgeva therapy.
XOLAIR

MEDICATION(S)
XOLAIR

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Asthma (init): Diagnosis of moderate to severe persistent allergic asthma. Positive skin test or in vitro reactivity to a perennial aeroallergen. Pretreatment serum immune globulin (Ig)E level between 30 to 700 IU/mL. Symptoms are not adequately controlled on a high-dose inhaled corticosteroid and a long-acting beta2-agonist combination for at least 3 months OR patient has intolerance or contraindication to high-dose ICS/LABA combination medications. Chronic Idiopathic Urticaria (CIU): Diagnosis of CIU. Persistent symptoms (itching and hives) for at least 4 consecutive weeks despite titrating to an optimal dose with a second generation H1 antihistamine. Patient has tried and had an inadequate response or intolerance to at least one of the following additional therapies: H2 antagonist, leukotriene receptor antagonist, H1 antihistamine, hydroxyzine, doxepin. Used concurrently with an H1 antihistamine.

AGE RESTRICTION
Asthma (init): Patient is 6 years of age or older. CIU (init): Patient is 12 years of age or older.

PRESCRIBER RESTRICTION
Asthma (init): Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. CIU (init): Prescribed by or in consultation with an allergist, immunologist, or dermatologist

COVERAGE DURATION
Asthma (init, reauth): 6 months CIU (init): 3 months (reauth) 6 months

OTHER CRITERIA
Asthma (reauth): Patient has experienced one or more of the following: Reduction in number of asthma exacerbations from baseline (eg, asthma exacerbation requiring treatment with systemic corticosteroids or doubling of inhaled corticosteroid [ICS] dose from baseline) or Improvement in forced expiratory volume in 1 second (FEV1) from baseline or Decreased use of rescue...
medications from baseline. CIU (reauth): Patients disease status has been re-evaluated since the last authorization to confirm the patients condition warrants continued treatment. Patient has experienced one or both of the following: Reduction in itching severity from baseline or Reduction in the number of hives from baseline.
MEDICATION(S)
XTANDI

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Metastatic castration-resistant prostate cancer (mCRPC): Diagnosis of mCRPC. History of failure, contraindication or intolerance to Zytiga.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed or in consultation with an oncologist or urologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
XYREM

**MEDICATION(S)**
XYREM

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Narcolepsy with cataplexy (Narcolepsy Type 1)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are present, AND symptoms of excessive daytime sleepiness (eg, irrepresible need to sleep or daytime lapses into sleep) are present. Narcolepsy without cataplexy (Narcolepsy Type 2)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are absent, AND symptoms of excessive daytime sleepiness (eg, irrepresible need to sleep or daytime lapses into sleep) are present, AND history of failure, contraindication, or intolerance to one of the following: 1) amphetamine-based stimulant (eg, amphetamine, dextroamphetamine), OR 2) methylphenidate-based stimulant.

**AGE RESTRICTION**
N/A

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
All uses (initial, reauth): 12 months

**OTHER CRITERIA**
Narcolepsy Type 1 (reauth): Documentation demonstrating a reduction in the frequency of cataplexy attacks associated with Xyrem therapy, OR documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy. Narcolepsy Type 2 (reauth): Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy.
YERVOY

MEDICATION(S)
YERVOY 50 MG/10 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Unresectable or metastatic melanoma: Diagnosis of unresectable, metastatic melanoma.
Cutaneous melanoma: Diagnosis of cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm. Patient has undergone resection, including total lymphadenectomy.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ZALTRAP

MEDICATION(S)
ZALTRAP 100 MG/4 ML VIAL

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Colon and/or rectal cancer: Diagnosis of metastatic colon and/or rectal cancer. Ziv-aflibercept is being used in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) regimen. Patient has disease that is resistant to or has progressed following an oxaliplatin-containing regimen [e.g., 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)].

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Subject to Part B vs. Part D review. Approve for continuation of prior therapy.
MEDICATION(S)
ZARXIO

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy, AND age greater than or equal to 55 years. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm^3), AND 2) patients with FN at high risk for infection-associated complications.

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by hematologist/oncologist except HIVN: Prescribed by hematologist/oncologist or
infectious disease specialist

**COVERAGE DURATION**
BMSCT, AML, CFN, secondary prophy of FN, NDDC:3mo or duration of tx. HIVN:6mo. Tx of FN, ARS:1 mo.

**OTHER CRITERIA**
HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm^3).
ZAVESCA

MEDICATION(S)
ZAVESCA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Gaucher disease: Diagnosis of mild to moderate Type 1 Gaucher disease. Patient is unable to receive enzyme replacement therapy due to one of the following conditions: allergy or hypersensitivity to enzyme replacement therapy, poor venous access, or unavailability of enzyme replacement therapy (e.g. Cerezyme, VPRIV).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
N/A

COVERAGE DURATION
Gaucher disease: 12 months

OTHER CRITERIA
N/A
ZEJULA

MEDICATION(S)
ZEJULA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy
ZELBORAF

MEDICATION(S)
ZELBORAF

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (eg, cobas 4600 BRAFV600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
**ZEMPLAR**

**MEDICATION(S)**
PARICALCITOL 10 MCG/2 ML VIAL, PARICALCITOL 2 MCG/ML VIAL, PARICALCITOL 5 MCG/ML VIAL

**COVERED USES**
All medically accepted indications not otherwise excluded from Part D.

**EXCLUSION CRITERIA**
N/A

**REQUIRED MEDICAL INFORMATION**
Diagnosis: secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 or CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).

**AGE RESTRICTION**
Injectable formulation is indicated for children 5 years and older.

**PRESCRIBER RESTRICTION**
N/A

**COVERAGE DURATION**
12 months

**OTHER CRITERIA**
For CKD Stage 5: patients should be treated only after their baseline serum calcium has been reduced to 9.5 mg/dL or lower.
ZEPATIER

MEDICATION(S)
ZEPATIER

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) For continuation of prior Zepatier therapy, AND C) Patient is not receiving Zepatier in combination with another HCV direct acting antiviral agent, AND D) patient does not have moderate to severe hepatic impairment (eg, Child-Pugh Class B or C), AND E) For genotype 1a, patient has been tested for the presence of NS5A resistance-associated polymorphisms (ie, polymorphisms at amino acid positions 28, 30, 31, or 93).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION
12 to 16 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA
N/A
ZOLINZA

MEDICATION(S)
ZOLINZA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Progressive, persistent or recurrent disease on or contraindication or intolerance to two systemic therapies (e.g., bexarotene, romidepsin, etc.).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ZORTRESS

MEDICATION(S)
ZORTRESS

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prevention of kidney transplant organ rejection: The medication is being used for prevention of kidney transplant organ rejection. Patient is at low-to-moderate immunologic risk. Patient is prescribed concurrent therapy with reduced doses of cyclosporine AND corticosteroids. Prevention of liver transplant organ rejection: The medication is being used for prevention of liver transplant organ rejection. Thirty (30) or more days have passed since the transplant procedure. Patient is prescribed concurrent therapy with reduced doses of tacrolimus and corticosteroids.

AGE RESTRICTION
All indications: 18 years of age or older

PRESCRIBER RESTRICTION
All indications: Prescriber is experienced in immunosuppressive therapy and management of transplant patients.

COVERAGE DURATION
12 months

OTHER CRITERIA
Subject to Part B vs. Part D review. Approve for continuation of prior therapy.
ZYDELIG

MEDICATION(S)
ZYDELIG

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Used in combination with Rituxan (rituximab). The patient has relapsed on at least one prior therapy (eg, purine analogues [fludarabine, pentostatin, cladribine], alkylating agents [chlorambucil, cyclophosphamide], or monoclonal antibodies [rituximab]). Patient is a candidate for Rituxan (rituximab) monotherapy due to presence of other comorbidities (eg, coronary artery disease, peripheral vascular disease, diabetes mellitus, pulmonary disease [COPD]). Follicular Lymphoma (FL): Diagnosis of FL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]). Small lymphocytic lymphoma (SLL): Diagnosis of SLL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
All uses: Prescribed by or in consultation with an oncologist/hematologist.

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ZYKADIA

MEDICATION(S)
ZYKADIA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC that is metastatic or recurrent. Tumor is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. History of failure or intolerance to Xalkori (crizotinib).

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prescribed by or in consultation with an oncologist

COVERAGE DURATION
12 months

OTHER CRITERIA
Approve for continuation of prior therapy.
ZYTIGA

MEDICATION(S)
ZYTIGA

COVERED USES
All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA
N/A

REQUIRED MEDICAL INFORMATION
Prostate Cancer: Diagnosis of metastatic castration-resistant (chemical or surgical) prostate cancer AND Used in combination with prednisone

AGE RESTRICTION
N/A

PRESCRIBER RESTRICTION
Prostate Cancer: Prescribed by or in consultation with an oncologist or urologist

COVERAGE DURATION
Prostate Cancer: 12 months

OTHER CRITERIA
Approve for continuation of prior therapy.